----

| 1.                      | Definitions      and Interpretation                                                        | 3      |
|-------------------------|--------------------------------------------------------------------------------------------|--------|
| 2.                      | Provision      of the Works and Services                                                   | 9      |
| 3.                      | Micromet's      Obligations                                                                | 12     |
| 4.                      | Governance                                                                                 | 13     |
| 5.                      | Inspections;      Person in Plant                                                          | 15     |
| 6.                      | Delivery,      Transportation of Product and Testing                                       | 16     |
| 7.                      | Price      and Terms of Payment                                                            | 17     |
| 8.                      | Intellectual      Property                                                                 | 18     |
| 9.                      | Warranties      and Indemnification                                                        | 20     |
| 10.                     | Confidentiality                                                                            | 24     |
| 11.                     | Option      for Commercial Supply Agreement                                                | 26     |
| 12.                     | Termination      of the Agreement, Termination of Certain Works and Services or      Slots | 26     |
| 13.                     | Non-Compete                                                                                | 28     |
| 14.                     | Technology      Transfer and License                                                       | 28     |
| 15.                     | Force      Majeure                                                                         | 29     |
| 16.                     | Governing      Law, Jurisdiction and Enforceability                                        | 29     |
| 17.                     | Notices                                                                                    | 30     |
| 18.                     | Illegality                                                                                 | 31     |
| 19.                     | Quality      Agreement                                                                     | 31     |
| 20.                     | Miscellaneous                                                                              | 32     |
|                    |                                                                                       |   |
| List      of Schedules: | 32                                                                                         |

----

| 1. | LONZA      SALES AG, of Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (herein      after referred to as "Lonza")    and |
|----|---------------------------------------------------------------------------------------------------------------------------------|

| 2. | MICROMET      AG, of Staffelseestrasse 2, D-81477 Munich, Germany (herein after referred      to as "Micromet"). |
|----|------------------------------------------------------------------------------------------------------------------|

| A. | Micromet      is the proprietor of the single-chain bispecific anti-CD19 antibody (CD19      BiTE®)      known as Blinatumomab or MT103 and controls a manufacturing process and a      cell line for manufacture of MT103;and |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | Lonza      has the expertise in the evaluation and production of monoclonal      antibodies for therapeutic use using different processes and cell lines in      accordance with international regulatory requirements;  and |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C. | Micromet      and Lonza have previously entered into a Services Agreement dated      September 28, 2009 regarding the performance of      a  [***]  to  [***]  for the      manufacturing of Micromet’s MT103 by Lonza;and |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D. | Micromet      wishes to contract Lonza for services relating to the development of the      Process (as defined herein) including all documentation, in each case,      suitable to obtain regulatory approval for commercialization of MT103 as a      therapeutic product and the manufacture of MT103 as described in this      Agreement, and |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| E. | Lonza      is prepared to perform such services for Micromet on the terms and      conditions set out herein. |
|----|---------------------------------------------------------------------------------------------------------------|

| 1. | Definitions      and Interpretation |
|----|-------------------------------------|

| "Affiliate" |   | means      any company, partnership or other entity which directly or indirectly      Controls, is Controlled by or is under common Control with the relevant      Party to this Agreement. "Control" or "Controlled" means the      ownership of more than fifty per cent (50%) of the issued share capital or      the legal power to direct or cause the direction of the general management      and policies of the Party inquestion; |
|-------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| "Agreement"          |   | means      this Development and Supply Agreement and the Schedules hereto, as amended      or varied from time to time by written agreement of the      Parties;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "Batch"              |   | means      the total Product (Drug Substance) obtained from one fermentation and      associated purification using the Process.  Batches which are to      be produced in accordance with cGMP are also referred to as "cGMP      Batches";                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "Batch      Release" |   | means      a release of any Batch by a Qualified Person for distribution or further      processing confirming that the Batch is in accordance with the relevant      requirements for human use (as defined in Directive 2001/83/EC for      medicinal products for human use);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "Cell    Line"       |   | means      the cell line controlled by Micromet and selected by Micromet for the      production of the Product, particulars of which are set out in Schedule      1;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "CEO"                |   | means      chief executive officer;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "cGMP"               |   | means      current good manufacturing practices and general biologics products      standards as promulgated under the European Commission Directives      91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC      respectively; the International Committee for Harmonisation (ICH) Q7A      Guideline on Good Manufacturing Practice for Active Pharmaceutical      Ingredients; the U.S. Federal Food, Drug and Cosmetic Act found in Title      21 of the U.S. Code of Federal Regulations (CFR), including but not      limited to Parts 210, 211 and Parts 11,  310 et seq., 600 to      610, the European Commission Guidelines of Good Manufacturing Practices      for Medicinal Products as promulgated under European Directive 2003/94/EC      (Eudralex – Volume 4) and the respective Japanese directives and      guidelines by the Japanese authorities, as applicable. Lonza meets EU GMP      requirements as defined in Eudralex - Volume 4 Good Manufacturing      Guidelines by the European Commission for medicinal products for human and      veterinary use (EU-GMP Guidelines); |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "cGMP      Product"  |   | means      Product which is required under Schedule 2 to      be manufactured in accordance with cGMP;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                 |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| "COO"                |   | means      chief operatingofficer;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

----

| "Deliverables"                        |   | means      the reports, documentation, information, material and Product which Lonza      is to make available to Micromet during the Project. The Deliverables and      the timelines to provide the Deliverables are set forth in the Project      Plan in Schedules 8 A and 8      B hereto;                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| "Engineering      Batch"              |   | means      the first Batch at scale after the pilot Batch in which Lonza will use      commercially reasonable efforts but does not warrant to meet      cGMP;                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| "External      Laboratories"          |   | means      any Third Party instructed by Lonza, with Micromet’s consent, to conduct      activities required to complete the Works and Services, including but not      limited to, Third Parties that synthesise DNA or perform tests on the Cell      Line, Product or materials derived therefrom; [***]                                                                                                                                                                                                                                                                                                                 |
| "Intellectual      Property"/"IP"     |   | means      all intellectual property rights, including (without limitation) patents,      patent applications, divisions, continuations, continuation-in-part      applications, divisionals, substitutions, confirmations, supplementary      protection certificates, reissues, utility models, trademarks, database      rights and copyrights and all inventions, know-how, trade secrets,      techniques and confidential information and other proprietary knowledge      and information which may subsist anywhere in the world, in each case for      their full term, and together with any renewals or    extensions; |
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| "Lonza"                               |   | means      Lonza Sales AG and its Affiliates Lonza Biologics plc of Slough, England,      Lonza Biologics Inc of Portsmouth, NH, USA, and Lonza Biologics Porriño      S.L. of Pontevedra-Galicia, Spain, and their successors in title and      lawful assigns;                                                                                                                                                                                                                                                                                                                                                             |
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| "Lonza Confidential      Information" |   | means      and includes Lonza Technology, any trade secrets or other confidential      information relating to Lonza's technology, business affairs or finances      of Lonza, or of any suppliers, agents, distributors, licensees or other      customers of Lonza and the commercial terms of this    Agreement;                                                                                                                                                                                                                                                                                                               |
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| "Lonza Know      How"                 |   | means      all technical and other information relating directly or indirectly to the      Lonza Process and/or the performance of the Works and Services, known to      Lonza from time to time, other than Micromet Confidential Information,      Micromet Know How and information in the public domain.  Without      limiting the foregoing, the Lonza Know How is identified in Schedule 4      hereto;                                                                                                                                                                                                          |

----

| "Lonza Patent      Rights"  |   | means      all patents, patent applications, divisions, continuations,      continuation-in-part applications, divisionals, extensions, substitutions,      renewals, confirmations, supplementary protection certificates and      reissues, throughout the world relating to the Lonza Process and/or the      performance of the Works and Services which from time to time Lonza is the      owner of or is entitled to use, and that is used in the performance of the      Works and Services.  Without limiting the foregoing, the Lonza      Patent Rights as of the Effective Date are listed in Schedule 5      hereto; |
|-----------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "Lonza      Process"        |   | means      the proprietary process of Lonza, including any modifications and      improvements, which is used for the manufacture of the Product      hereunder;                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "Lonza      Technology"     |   | means      the Lonza Know How and the Lonza Patent Rights;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "      [***] "              |   | means  [***]      ;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "      [***] "              |   | means      the [***] Agreement between [***] and [***] dated [***] and attached      hereto at Schedule 9;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "Micromet"                  |   | means      Micromet AG and its existing Affiliates which are engaged in the research      and development of BiTE®      antibodies, and their successors in title and lawful    assigns;                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "Micromet      Confidential |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Information"                |   | means      and includes Micromet Materials, Micromet Technology and the Results, any      trade secrets or other confidential information relating to Micromet's      technology, development strategies, business affairs or finances of      Micromet, or of any licensors, suppliers, agents, distributors or other      contractors of Micromet, and the commercial terms of this      Agreement;                                                                                                                                                                                                                                       |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "Micromet Know      How"    |   | means      all technical and other information relating directly or indirectly to the      Micromet Process, the Cell Line and the Micromet Materials, known to      Micromet from time to time, other than Lonza Confidential Information,      Lonza Know How and information in the public domain.  Without      limiting the foregoing, the Micromet Know How is identified in Schedule 6      hereto;                                                                                                                                                                                                                        |
|                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| "Micromet      Materials"   |   | means      the materials and documentation supplied by Micromet to Lonza (including      but not limited to  [***] and  [***]      ).  Without limiting the foregoing, the Micromet Materials to be      transferred are listed in Schedule 1      hereto;                                                                                                                                                                                                                                                                                                                                                    |

----

| "Micromet Patent      Rights" |   | means      all patents, patent applications, divisions, continuations,      continuation-in-part applications, divisionals, extensions, substitutions,      renewals, confirmations, supplementary protection certificates and      reissues, throughout the world relating to the Micromet Process, the Cell      Line and the Micromet Materials which from time to time Micromet is the      owner of or is entitled to use, and that is used in the performance of the      Works and Services.  Without limiting the foregoing, the      Micromet Patent Rights as of the Effective Date are listed in Schedule 7      hereto; |
|-------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Micromet      Process"       |   | means      the process (including but not limited to the  [***] process and      the  [***] process) for the production of Product which is owned      or Controlled by Micromet and made available to Lonza hereunder      for  [***] with the  [***] , further improvement      and/or production of the Product;                                                                                                                                                                                                                                                                                   |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Micromet      Technology"    |   | means      the Micromet Know How and the Micromet Patent Rights;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| " [***] "                     |   | means      any  [***] of  [***] , including  [***]      and  [***] ;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "MT103"                       |   | means      Micromet's single-chain bispecific anti-CD19 antibody (CD19 BiTE®)      also known as Blinatumomab;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Party"/"Parties"             |   | shall      mean Lonza or Micromet, or Lonza and Micromet, as the context      admits;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Price"                       |   | means      the price specified in Schedule 3 for      the Works and Services;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Process"                     |   | means      the process used by Lonza for the production of Product from the Cell Line      in accordance with this Agreement, which may combine elements of the      Micromet Process and of the Lonza Process, and is modified and/or improved      hereunder;                                                                                                                                                                                                                                                                                                                                                                               |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Product"                     |   | means      MT103 manufactured under this Agreement (including any sample thereof),      particulars of which are set out in Schedule 1 and      includes all derivatives thereof;                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Project"                     |   | means      the program described in the Project Plan;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| "Project      Manager"        |   | means      a Party's representative who is responsible for the coordination and      supervision of the Project in accordance with Clause 4.1      below;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

----

| "Project      Plan"       |   | means      the plan describing all activities to be performed under this Agreement,      including any update and amendment of the Project Plan the Parties may      agree from time to time, and attached hereto as Schedules 8 A and 8      B;                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Project      Team"       |   | means      the working group described in Clause 4.2;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Qualified Person"/"QP"   |   | means      a person confirming that the Batch is in accordance with the relevant      requirements (as defined in Directive 2001/83/EC for medicinal products      for human use);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Results"                 |   | means      the Product, any inventions, discoveries, know how, data, Deliverables,      documentation, reports, materials, writings, processes, methods and other      information, recorded in any form, that are discovered, conceived, reduced      to practice, developed or otherwise generated by Lonza, which are related      to the Works and Services and conceived through the performance of the      Works and Services, and any Intellectual Property pertaining to any of the      foregoing (including the  [***] Intellectual Property), provided, however, that      "Results" shall exclude  [***] and  [***] Intellectual      Property; |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Service      Agreement"  |   | means      the agreement between the Parties dated September 28, 2009 regarding      the  [***] of  [***]  for the production of      Product using the  [***] and the  [***]    ;                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Specifications"          |   | means      the specifications for Drug Substance.  The Specifications and      the specifications for Drug Product regarding the testing of Drug Product      by Lonza are set out in Schedule      2;                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Steering      Committee" |   | means      the committee described in Clause 4.3;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Terms of      Payment"   |   | means      the terms of payment specified in Schedule      3;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Third    Party"          |   | means      any party other than Lonza and Micromet;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| "Works and      Services" |   | means      all or any part of the works and services which are the subject of this      Agreement, particulars of which are set out in Schedules 8 A and 8      B.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

----

| 2. | Provision      of the Works and Services |
|----|------------------------------------------|

| 2.1 | Lonza      shall diligently carry out the Works and Services as provided in Schedule 8 A –      and in Schedule      8 B, once it is finalized - and shall use all reasonable efforts to      achieve the estimated timescales set out in that Schedule.  The      Parties agree that the Works and Services set forth in Schedule 8 B are      rough estimates only, and the Parties shall updated and refine such      Schedule 8 B after the transfer of the Micromet Materials and      establishment of the Process at Lonza.  Lonza shall perform the      Works and Services under this Agreement according to the current industry      standards and subject to terms and conditions as set out      herein.  Lonza shall at all times use reasonable and adequate      safety and protection measures to ensure, as far as is reasonably      possible, that the Results are not endangered by an interruption of      Lonza's research and developmentactivities. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 | Lonza      shall do all that is reasonably possible to meet the objectives under the      Project Plan, including diligence obligations and commercially reasonable      flexibility regarding alternative work packages and capacity reservations      under this Agreement. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.3 | Micromet      shall make available to Lonza a data package comprising the Micromet Know      How which is reasonably required to perform the Works and Services and the      Parties shall collaborate to assist Lonza in evaluating such Micromet Know      How.  Without undue delay upon completion of the Services      Agreement and delivery of such Micromet Know How, however, no later than      within  [***]  thereafter, Lonza shall inform Micromet      whether the  [***] , the  [***]  and      the  [***]  meet the particulars set out in Schedule 1 and      are suited for the performance of the Works and Services      hereunder.  If the  [***] ,      the  [***]  and/or the  [***]  do      not meet the particulars set out in Schedule 1,      Lonza and Micromet shall enter into good faith discussions in order to      identify a  [***] , a  [***]  or      other  [***]  for the Works and Services and to agree      on the terms and conditions and adjustments to the Project Plan to      minimize any delay.  If the Parties are unable to agree on      an  [***]  or  [***]  and the      terms and conditions to use such  [***] or  [***]      within  [***]  after completion of the later of (i)      completion of services under the Services Agreement or (ii) transfer of      the Micromet Materials and Micromet Technology,  [***] shall      have the option to  [***] in accordance with  [***]      and without further  [***] or to  [***]      under  [***] |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.4 | Lonza      shall manufacture cGMP Product to meet the Specifications provided that there      shall be  [***] to meet the Specifications in respect of the      [***] and the  [***]  manufactured or in respect of      the  [***] following any change in the  [***]      .  If the  [***]  or a combination of      the  [***]  and the  [***]  is      used, then in addition to the above, Lonza shall be under no obligation to      meet certain  [***] in  [***]  in respect      of  [***] until a  [***] does meet  [***]      .  In the event the  [***]  does not meet      the Specifications, the Parties shall promptly meet through the Steering      Committee to discuss and agree on how to ensure that the Specifications      can be met, which agreement may include a modification of the Project      Plan. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.5 | Owing      to the unpredictable nature of the biological processes involved in the      Works and Services, the timescales set down for the performance of the      Works and Services (including without limitation the dates for production      and Delivery of Product) and the quantities of Product for Delivery set      out in Schedules      8 A and 8 B are estimated only.  In the event any Party      realizes that the Project Plan needs to be changed, e.g., for a delay of      Works and Services owing to technical or scientific difficulties, such      Party shall immediately inform the Project Team hereof and the Parties,      through the Steering Committee (if needed), shall use commercially      reasonable efforts to come to an adequate solution and agree on an      adequate amendment of the Project Plan.  In particular, Lonza      will use commercially reasonable efforts to  [***]  as      early as possible, in the event any of the  [***] , provided always      that  [***]  are taken into      account. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.6 | Lonza      will use its reasonable efforts to perform any additional work which may      become necessary to manufacture Product for  [***]      .  If such additional work leads to additional costs, Lonza will      provide a quotation for such additional work.  In case the      Parties agree on the additional work and the costs for such additional      work, Lonza shall perform additional work to sustain the progress of the      Project on terms and conditions to be agreed by the Parties and defined in      an amendment to the Project Plan.  If further quantities of      Product are required for  [***]  which are not part of      this Agreement, the Parties will discuss in good faith how Lonza can      satisfy Micromet's needs for such additional  quantities. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.7 | Without      prejudice to Lonza’s obligations under Clauses 2.1 and 2.2 and the      termination rights under Clause 12,      Micromet  [***]  of the Works and Services or      to  [***] the Works and Services on grounds of late performance,      late Delivery or failure to produce the estimated quantities of Product      for Delivery.  Lonza shall not be liable for any loss, damage,      costs or expenses of any nature, whether direct or consequential,      occasioned by: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.8 | Lonza      shall comply with all applicable laws and regulations regarding the cGMP      production, including but not limited to the EU-GMP Guidelines (Eudralex –      Vol. 4), FDA regulations, Japanese regulations and the International      Committee for Harmonisation regulatory requirements from time to time      applicable to the Works and Services as set out in Schedules 8 A and 8      B. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.9 | Lonza      shall not use the Cell Line, the Process (not including the Lonza      Process), the Micromet Materials or the Micromet Technology (or any part      thereof) for any purpose other than the performance of the Works and      Services under this Agreement. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.10  | Lonza      shall: |
|------------|-------------------|

|   | (a) | at      all times use all reasonable endeavours to keep the Cell Line and/or the      Micromet Materials secure and safe from loss and damage in such manner as      Lonza stores its own material of similar nature during the term of this      Agreement, and obtain and maintain an appropriate insurance against the      risks of loss and damage; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | during      the performance of the Works and Services, inform Micromet as soon as      reasonably possible upon request about all ongoing    activities; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | not      part with possession of the Cell Line and/or the Micromet Materials or the      Product, save for the purpose of activities at the External Laboratories      or as otherwise authorised in writing by  Micromet; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | store      Micromet Materials in accordance with applicable laws, industry standards      and the specifications set forth in Schedule 1,      furthermore, store the Cell Line and the cell banks ( [***]      and  [***] ) at at least two (2) different and controlled sites      under cGMP conditions; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (e) | audit      all External Laboratories in accordance with GxP guidelines and confirm      the performance of such audit to Micromet in writing;  and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | procure      that all External Laboratories are subject to obligations of confidence      substantially in the form of those obligations of confidence imposed on      Lonza under this Agreement. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.11 | Lonza      will not (i) directly or indirectly, take any steps to ascertain      the  [***] of any  [***]  provided by      Micromet and or a  [***] , and (ii) use      Micromet's  [***]  for any purpose other than      manufacturing the Product.  In the event Lonza ascertains or      receives the recipe of any of      Micromet's  [***]  through no fault of its own, Lonza      shall promptly inform Micromet of such event and destroy such      information. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.12 | Lonza      and Micromet will exchange details of the  [***]  in      order to  [***]  that will be used  [***]      .  Lonza will obtain Micromet's consent regarding      its  [***] , which Micromet shall not unreasonably      withhold.  Lonza shall use reasonable commercial endeavours to      ensure continuity of supply, through the  [***] of      a  [***]  where possible,  [***]      establishment  [***] second source  [***] same      supplier (e.g. second production site)  [***]      establishment  [***] supply  [***] emergency      plan/security stock. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.13 | Lonza      agrees to maintain proper records (the "Records") in respect of      its performance of the Works and Services, including any Results made as      part of the Works and Services.  Upon written request by      Micromet, Lonza shall provide copies of the Records or any part(s)      thereof, redacted with regards      to  [***]  and  [***]  to      Micromet.  As part of keeping the Records, Lonza shall ensure      that all of its personnel and all of its agents abide by the regulations      of the International Committee for Harmonisation as per Clause      2.8. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.14 | Lonza      shall: |
|------|-------------------|

|   | (a) | make      available to Micromet the Deliverables set forth in the Project      Plan; |
|--------|-----|--------------------------------------------------------------------------------------|

|   | (b) | make      available to Micromet (i) upon completion of any milestone as outlined in      the Project Plan and or (ii)  [***] of the  [***] of      the Works and Services and upon reasonable request of Micromet, (i.e., if      Micromet requires such documentation for regulatory purposes or for own      development purposes and provided that such      documentation – in Lonza's reasonable opinion – is accurate); copies of      all relevant documentation and information resulting from the Works and      Services and relating to the Product in order to enable Micromet to      evaluate the status and to meet any statutory or regulatory      requirements.  The documentation and information shall be      provided in the CTD format.  The documentation and information      shall include but not be limited to the  [***]      of  [***] and the  [***] , a  [***]      of  [***] of the  [***] , a  [***] ,      including a  [***] and a [***] issued by and in responsibility      of a  [***] ,  [***] of  [***] and      the  [***] of  [***] for the  [***] or      equivalent in other  [***] ) in  [***] and      for  [***] of such  [***] to the  [***]      .  For the avoidance of doubt, the preceding sentence does not      require  [***] to provide  [***] with  [***]      of the  [***] or other  [***]  except if      requested by  [***] ;[***] |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | support      IND updates and CTAs as well as the submission of dossiers for NDA/MAA      approval; |
|--------|-----|----------------------------------------------------------------------------------------------------|

|   | (d) | make      available to Micromet, upon completion of each stage as outlined in the      Project Plan and upon request of Micromet, material ( [***] and the like)      resulting from the Works and Services in order to enable Micromet to test      the supernatant, antibody, cells, Product, and the  like; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (e) | assist      Micromet in respect to regulatory requirements concerning the CMC-part,      including but not limited to the  [***] for  [***]      and  [***] ; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | reasonably      support Micromet regarding regulatory matters.  Such support      shall include an obligation to make Micromet aware of any specific      regulatory requirements relating to Lonza’s activities, to accompany      Micromet to meetings with the regulatory authorities      upon  [***]  prior written notice by Micromet (or use      reasonable commercial endeavours to support Micromet where shorter notice      is provided by a regulatory authority), to prepare such meetings jointly      with Micromet, and to actively participate in scientific advice meetings;      and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | promptly      inform Micromet about any existing or potential future issues      with  [***] that  [***] regarding any  [***]      or  [***]used  [***] |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The      Deliverables and the provision of the Deliverables are defined in more      detail in the Project Plan. |
|--------|------------------------------------------------------------------------------------------------------------------|

| 2.15 | Lonza      shall from time to time offer to Micromet  [***] of      its  [***] and  [***]  (as identified in      Schedule 4).  Such new version shall be made available at the      price set forth in the Technology Transfer and License Agreement in Schedule 14      hereto, if applicable, with the only further compensation being for      additional Works and Services which may be required to implement such      improvement or new version for the manufacture of the    Product. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.16 | Any      subcontracting of Works and Services to be performed hereunder by Lonza to      Third Parties requires the prior written consent of    Micromet. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Micromet's      Obligations |
|----|-----------------------------|

| 3.1 | Following      the Effective Date (if not already forwarded to Lonza during the Services      Agreement) and upon conclusion of  [***] the  [***] of      some of the  [***] and  [***]  attached      hereto as Schedule 9,      Micromet shall supply to Lonza the Micromet Know How, together with full      details of any hazards relating to the Cell Line, the Micromet Process      and/or the Micromet Materials, their storage and use, in each case, to the      extent required by Lonza to perform the Works and Services.  For      the avoidance of doubt, the  [***]  is embodied in      the  [***] the  [***] and      the  [***]  and is not disclosed as a separate set of      documents.  On review and approval by Lonza’s safety committee      of this Micromet Technology, the Cell Line, the Micromet Process and/or      the Micromet Materials shall be provided to Lonza at Lonza’s      request.  Property in the Cell Line, the Micromet Process and/or      the Micromet Materials and/or the Micromet Technology supplied to Lonza      shall remain vested in Micromet. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | Unless      the Parties agree otherwise during the term of this Agreement, Micromet or      Micromet's Third Party supplier will supply to Lonza the  [***]      and  [***]  necessary for the manufacture of      Product.  Lonza shall not, directly or indirectly, take any      steps to  [***] the  [***] of any      such  [***] and  [***]  provided by      Micromet.   Similarly, should the Lonza Process be used in      the manufacture of the Product, Micromet shall not, directly or      indirectly, take any steps to  [***] the  [***] of      any  [***] and  [***]  provided by      Lonza. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.3 | Micromet      shall pay the Price set out in Schedule 3 for      provision of the Works and Services together with any additional costs and      expenses that fall due under this Agreement in accordance with the Terms      of Payment. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4 | Micromet      hereby grants Lonza the non-exclusive right to use the Cell Line, the      Micromet Process, the Micromet Materials, and the Micromet Technology      during the term of this Agreement and solely for the purpose of this      Agreement.  Micromet acknowledges that Lonza does not require a      separate licence to Micromet Confidential Information as all necessary      licences are contained in the first sentence of this clause      3.4. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5 | From      time to time, as soon as reasonably possible and with at      least  [***]  advance notice, Lonza may submit to      Micromet a written request to provide or have provided consulting services      to Lonza with respect to the Micromet Process, which request will include      the specifics of the consulting services being requested, and Micromet      will use reasonable efforts to provide or have provided such consulting      services. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.  | Governance |
|----------|------------|

| 4.1 | Designation of Project      Manager:  Lonza and Micromet shall each identify a      Project Manager who will be responsible for the coordination and      supervision of the Project including communication of all instructions and      information concerning the Project to the other Party.  A      written protocol of such communication shall be provided by the Project      Managers.  Each Project Manager will be available on an agreed      weekly basis for consultation at prearranged times during the course of      the Project.  In the absence of the Project Manager, a      substitute shall be appointed.  Additional modes or methods of      communication and decision making may be implemented with the written      consent of each Party. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | Project      Team:  The Parties shall form a Project Team to which      Micromet will delegate professionally and technically qualified      representatives (e.g., qualified in upstream process, downstream process,      analytics, quality assurance and regulatory matters).  Each      Project Team member shall have knowledge and ongoing familiarity with the      Project and will possess the authority to make decisions on matters raised      in the Project Team.  Each Party shall have the right to      substitute different representatives as its members of the Project Team as      needed from time to time.  Each Party shall also be entitled to      invite other employees as ad hoc guests to address specific technical or      commercial issues related to the Project.  Consultants of a      Party or other Third Parties may be invited, provided that they are      bound by a confidentiality obligation which is substantially similar to      the Parties' obligations under Clause 10below. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The      Project Team shall oversee the Project.  Prior to each meeting      of the Project Team the Parties will distribute to each other written      copies of all materials, data and information arising out of the conduct      of their activities hereunder.  Unless otherwise agreed, Lonza      shall present any suggestions regarding the Project Plan and/or      specifications of the Project to the Project Team for discussion and      approval by Micromet. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | Each      Party shall bear its own travel and accommodation costs.  The      meetings of the Project Team may also be held by telephone or video      conference if mutually agreed by the Project Team members.  It      is the right of each Party to call for a Project Team meeting upon written      request at any time.  In that case the meeting will be held at a      time and location to be agreed between the Project Team      members. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The      inviting Party shall prepare minutes of the meeting which shall be      circulated promptly following themeeting. |
|--------|----------------------------------------------------------------------------------------------------------------------------|

| 4.3 | Steering      Committee:  The Parties shall form a Steering Committee      to which each Party will delegate two (2) executive employees, who are      familiar with the Project.  The Steering Committee shall have      general oversight and review of the activities of the Project Team and      shall be responsible for resolving any issues referred to the Steering      Committee by the Parties. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The      Steering Committee shall meet in person or via teleconferences      within  [***]  after a written request by either Party      to the other Party, or sooner, if required, and calendar quarterly, if      possible towards the end of a stage of the Project.  The request      shall describe the matter in dispute and the solution which the requesting      Party proposes to be decided. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The      Steering Committee will take action by unanimous consent of its members,      with each representative having a single vote, or by a written resolution      signed by all of the representatives.  If the Steering Committee      is unable to reach unanimous consent on a particular matter, then the      matter will be referred to a personal face-to-face meeting between      Lonza's  [***]  and the  [***]  of      Micromet, who in each case may not be a member of the Steering Committee      and both of whom shall act in good faith and discuss the issue to seek a      resolution amicably acceptable to both Parties and if resolved the      resolution shall be binding and final.  The meeting shall take      place within  [***]  of the relevant      referral.  In case such persons cannot agree within      further  [***]  after such face-to-face meeting, then      the following shall apply: |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | If      the dispute is predominantly concerned with scientific or technical issues      then the entire dispute shall be referred to independent experts on who      the Parties agree as set forth hereinafter:  Each Party is      entitled to propose one (1) independent expert and the other Party shall      not unreasonably withhold its consent to the appointment of such      expert.  The Parties will make available the same set of      documents to both experts and both experts shall provide their expert      opinion in English language within  [***]  after the      second expert has been appointed.  If the two (2) experts come      to dissenting opinions and are unable to solve the dispute among      themselves, a third expert shall be appointed either jointly by the      Parties or by the President of the German Association of the      Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie,      BPI), if the Parties cannot agree, who is an expert in the particular      scientific or technical area at issue and who shall act as an expert and      not an arbitrator.  Such third expert shall have access to the      written opinions of the two other experts as well as to all documents      which were made available to the two experts.  The third expert      shall then approve either one of the two opinions of the first two      experts, and such opinion approved by the third expert shall be considered      final and binding on the Parties except if there has been a manifest error      on the face of the decision whereupon the Parties may revert to their      respective remedies under Clause 16 below.  The reasonable costs      of the experts shall be paid or refunded, as the case may be, by the      non-prevailing Party. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (ii) | If      the dispute is predominantly concerned with an issue other than scientific      or technical then it shall be resolved in accordance with Clause 16      below. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.  | Inspections;      Person in Plant |
|----------|-----------------------------------|

| 5.1 | As      more fully set out in the Quality Agreement in Schedule 10      hereto, Lonza grants to Micromet and/or its consultant the right to      inspect and audit Lonza's Affiliate’s facility located in Slough,      Berkshire, United Kingdom ("Facility") as well as      the documentation generated in connection with the manufacture and testing      of Product including all relevant standard operating procedures.       Lonza grants the right to perform  [***] standard cGMP      compliance audit per year, not to exceed  [***]      and  [***]  at a time mutually agreed between Micromet      and Lonza.  Micromet can perform  [***]  cGMP      batch documentation audit per cGMP batch which would be scheduled as      appropriate in the project plan.  Moreover, Micromet is entitled to      perform additional audits in the event of complaints, major or critical      deviations or other enquiries by regulatory authorities without any fee,      and if necessary, on short-term notice.  Micromet will discuss the      results of any inspection with Lonza.  Any inspection by Micromet      does not relieve Lonza of its obligations to comply with all applicable      laws and does not constitute a waiver of any right otherwise available to      Micromet.  As more fully set out in Clause      5.3,  [***]  is also entitled to attend all production      campaigns of the Product at theFacility. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2 | As      more fully set out in the Quality Agreement in Schedule 10      hereto, an employee and/or consultant and /or successor of Micromet or      Micromet’s sublicensee(s) of the Product will have the right to be present      as a silent observer at any announced visit to Lonza by any regulatory      authority relating to the manufacture of Product for clinical trials.      Furthermore, Lonza will inform Micromet of the results of any inspection      by a regulatory authority (subject to any restraints placed on Lonza by      such regulatory authority, Lonza Confidential Information which Micromet      does not require for purposes of this Agreement or customer      confidentiality) that does or could reasonably be expected to affect the      manufacture of Products. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3 | Lonza      agrees to have an employee or consultant of Micromet be present at the      Facility in order to observe the Works and Services performed by Lonza or      its Affiliate ("Person-in-Plant" or      "PiP") in      accordance with this Clause 5.3.  Upon request of Micromet,      Lonza shall grant the PiP access to the Facility where the Works and      Services are performed.  Such visits, shall last not longer      than  [***] , will take place no more than  [***]      a  [***]  during regular business hours and      upon  [***]  prior notice to Lonza, provided, however, that      PiP will be entitled to perform additional visits that could last up to      the full length of a cGMP Batch's (and/or consolidation and/or pilot      Batch's) manufacturing process subject to Lonza’s consent not to be      unreasonably withheld or delayed, and further providedthat PiP will be      entitled to perform visits upon immediate notice in the event of      complaints or failures which may endanger the  Project. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.4 | Notwithstanding      Clauses 5.1, 5.2 and 5.3, Micromet acknowledges and accepts that the      Facility is a multi-customer facility, and that the PiP’s movement about      and access to the Facility may be restricted and shall be subject to      supervision by Lonza. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.  | Delivery,      Transportation of Product andTesting |
|----------|-----------------------------------------------------|

| 6.1 | Subject      to Clause 2.4, Product shall be Delivered in accordance with the      Specifications.  Delivery shall be      made  [***]  (as defined by Incoterms 2000) which      means (a) when  [***] places  [***] at      the  [***] at  [***]      and  [***]  and (b) risk and title to Product      pass  [***] .  Subject to Clause 6.2, Lonza shall      deliver to Micromet the Certificate of Analysis, the Certificate of      Compliance, issued by and in responsibility of a Qualified Person (Batch      Release) and such other documentation as is reasonably required to meet      all applicable statutory and regulatory requirements not later than the      date of Delivery.  Transportation of Product, whether or not      under any arrangements made by Lonza on behalf of Micromet, shall be made      at the  [***] of  [***].. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2 | At      Micromet's request, Lonza will Deliver Product  [***] prior to      delivery of the  [***] and      the  [***]   Such request shall be accompanied by      Micromet's written acknowledgement that the Product has been Delivered      without the transmittal to Micromet of the Certificate of Analysis and the      Batch release documents (QP release), that accordingly the Product cannot      be administered to humans until transmittal of the Certificate of      Analysis, Certificate of Compliance (possibly in one document) and the      Batch release documents (QP release) and that Micromet nevertheless      accepts full risk of loss, title and ownership of the      Product.  The Delivery of Product in quarantine shall be subject      to such testing requirements as Lonza may reasonably require, and      the  [***]  period referred to in Clause 6.9 shall run      from Delivery in quarantine of the Product to  Micromet. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3 | Unless      otherwise agreed, Lonza shall package and label Product for Delivery in      accordance with its standard operating procedures.  It shall be      the responsibility of Micromet to inform Lonza in writing in advance of      any special packaging and labeling requirements for      Product.  All additional costs and expenses of whatever nature      incurred by Lonza in complying with such special requirements shall be      charged to Micromet in addition to thePrice. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.4 | If      requested in writing by Micromet, Lonza will (acting as agent for      Micromet) arrange for storage in accordance with the storage conditions in      Schedule      1 and for insurance of Product whilst held by Lonza after Delivery      (awaiting transportation) for up to  [***]  after QP      release of the Batch, and in exceptional cases for a maximum      of  [***] , on terms equivalent to those under which Lonza      stores and insures product prior to Delivery.  All additional      costs and expenses of whatever nature incurred by Lonza in arranging such      storage and insurance shall be charged to Micromet in addition to the      Price. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.5 | If      requested in writing by Micromet, Lonza will (acting as agent of Micromet      for such purpose) arrange the transportation of Product from Lonza’s      premises to the destination indicated by Micromet together with insurance      cover for Product in transit at its invoiced value.  All      additional costs and expenses of whatever nature incurred by Lonza in      arranging such transportation and insurance shall be charged to Micromet      in addition to the Price. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.6 | Where      Lonza has made arrangements for the transportation of Product, Micromet      shall diligently examine the Product as soon as practicable after      receipt.  Notice of all claims (time being of the essence)      arising out of: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | visible      damage (i.e., visible without inspection and testing) to or total or      partial loss of Product in transit shall be given in writing to Lonza and      the carrier within  [***]  of receipt by Micromet;      or |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | non-Delivery      shall be given in writing to Lonza      within  [***]  after the date of Lonza’s dispatch      notice. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.7 | Any      Product Delivered hereunder shall, at the time of Delivery conform to the      Specifications (subject to Clause 2.4 above) and have been manufactured in      accordance with cGMP (not including the pilot Batch and Engineering Batch)      and applicable laws.  Lonza and Micromet shall use all      commercially reasonable efforts to resolve a non-conformity issue and      resume re-delivery of Products at the earliest time      possible.  Any dispute regarding the conformity of Products      which cannot be settled within  [***]  after receipt      of a detailed written notice of rejection shall be submitted for      resolution to the SteeringCommittee. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.8 | Micromet      shall make damaged Product and associated packaging materials available      for inspection and shall comply with the requirements of any insurance      policy covering the Product notified by Lonza to      Micromet.  Lonza shall offer Micromet all reasonable assistance      (at the cost and expense of Micromet) in pursuing any claims arising out      of the transportation of Product. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.9 | Promptly      following receipt of Product or any sample thereof, Micromet may carry out      any of the agreed tests outlined or referred to in Schedule      11.  Subject to Clause 2.4, if such tests show that the      Product fails to meet Specifications, Micromet shall give Lonza written      notice thereof within  [***]  from the date of      Delivery and shall return samples of such Product to Lonza’s premises for      further testing and Micromet shall store the remainder of Product in      quarantine.  In the absence of such written notice and subject      to any hidden defect which did not appear in the tests carried out by      Micromet in accordance with Schedule 11,      Product shall be deemed to have been accepted by Micromet as meeting the      Specifications.  Subject to Clause 2.4, if Product returned to      Lonza fails to meet the Specifications and if such failure is not due (in      whole or in part) to acts or omissions of Micromet or any Third Party      after Delivery,  [***] shall at  [***]      discretion  [***] that  [***] to  [***] of      such  [***] or  [***] and  [***] and      further  [***] all  [***] regarding      the  [***] to  [***] In the event  [***]      to  [***] such  [***] shall use  [***]      to  [***] with the  [***] to its  [***]      to  [***] in the  [***].. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.10 | Subject      to Clause 2.4, if there is any dispute concerning whether Product returned      to Lonza fails to meet the Specifications or whether such failure is due      (in whole or in part) to acts or omissions of Micromet or any Third Party      after Delivery, such dispute shall be referred for decision to an      independent expert (acting as an expert and not as an arbitrator) to be      appointed and paid in accordance with Clause 4.3 (i)  above. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.11 | The      provisions of Clauses 6.9 and 6.10 shall be the sole remedy available to      Micromet in respect of Product that fails to meet the      Specifications. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.  | Price      and Terms of Payment |
|----------|---------------------------------|

| 7.1 | Unless      otherwise indicated in writing by Lonza, all prices and charges are      exclusive of Value Added Tax or of any other applicable taxes, levies,      imposts, duties and fees of whatever nature imposed by or under the      authority of any government or public authority, which shall be paid by      Micromet (other than taxes on Lonza’s income).  Payments shall      be made in accordance with the Terms of Payment in Schedule 3      hereto.  Lonza will provide to Micromet in regular intervals      upon amendments to the Project Plan updated payment plans.  All      invoices are strictly net and payment must be made      within  [***]  of date of invoice.  Payment      shall be made without deduction, deferment, set-off, lien or counterclaim      of any nature. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7.2  | In      default of payment on duedate: |
|-----------|----------------------------------------|

|   | (a) | interest      shall accrue on any amount overdue at the rate      of  [***]  above the base lending rate from time to      time of National Westminster Bank plc, interest to accrue on a day to day      basis both before and after judgment;and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Lonza      shall, at its sole discretion, and without prejudice to any other of its      accrued rights, be entitled to suspend the provision of the Works and      Services or to treat this Agreement as repudiated on not less      than  [***]  prior notice in writing to Micromet given      at any time thereafter. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.  | Intellectual      Property |
|----------|----------------------------|

| 8.1 | Neither      Party will, as a result of this Agreement, acquire any right, title, or      interest in any Intellectual Property that the other Party owns or      Controls as of the Effective Date, or that the other Party obtains      ownership or Control of separate and apart from the performance of the      Works and Services under thisAgreement. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2 | [***]      acknowledges and agrees that, subject to Clause 8.3, any and      all  [***] shall  [***] shall promptly and      fully  [***] all  [***] to  [***]      and  [***] to  [***] that  [***]      and  [***] or  [***] may  [***]      and  [***] and  [***] to  [***] to      the  [***] of  [***]    and  [***] |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3 | [***]  shall      own all right, title and interest in  [***]  which as      used in this Agreement means Intellectual Property that  [***] ,      contractors or agents develops, conceives, invents, reduces to practice or      makes in the course of performance of the Works and Services and that (i)      arises from or relates to  [***]  or  [***]      ; and (ii) is severable from      the  [***]  and  [***] ; and (iii) does not      reveal or disclose the  [***] , or Works and Services performed      under this Agreement.   [***]  shall      provide  [***]  with a general description of      any  [***] Intellectual Property in the event that any is      developed, in order to enable  [***]  to make an      assessment as to whether  [***]  would like to use      the  [***] Intellectual Property under the  [***]      . |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4 | Except      for and not including the  [***] Intellectual Property, Micromet      shall own all right, title, and interest in any and all  [***]      and  [***] that  [***] conceives, invents, reduces to      practice, develops or makes, solely or jointly with Micromet or others, in      the course of performance of the Works and Services or as a result      of  [***] of  [***] or  [***] (collectively,      the " [***] Intellectual      Property"). [***] hereby assigns and transfers to Micromet and      shall continue to assign and transfer to  [***] of its right,      title and interest in any  [***] Intellectual Property,      and  [***] hereby accepts such assignment and transfer. [***]      shall promptly disclose  [***] in writing all  [***]      Intellectual Property. [***] shall execute, and shall      require  [***] personnel  [***] to execute, any      documents required to confirm  [***] ownership of the      New  [***] Intellectual Property, and any documents required to      apply for, maintain and enforce any patent or other right in      the  [***] Intellectual      Property.  Upon  [***] request and at  [***]      and at  [***] shall assist  [***] as may be necessary      to apply for, maintain and enforce any patent or other right in the      [***]  Intellectual Property.  For the avoidance of      doubt, the Parties agree that the term " [***] Intellectual Property"      shall not under any circumstances be interpreted or defined to include any      " [***] Intellectual Property". |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 8.5 | In      relation only to      the  [***]  and  [***]  (and no      other product),  [***]  hereby grants  [***]      , and  [***]  hereby      accepts  [***]  under and to all  [***]      Intellectual Property, to the extent such  [***] Intellectual      Property are necessary or useful to research, develop, have developed,      conduct clinical trials for, formulate, manufacture, have manufactured,      test, seek regulatory approval for, market, have marketed, commercialize,      have commercialized, make, have made, use, sell, have sold import, have      imported and distribute and have      distributed  [***]  or  [***]      .  For the avoidance of doubt, the nature of the above exclusive      licence is as follows: |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | [***]  ownership      of  [***] Intellectual Property as set      out  [***]  is notaffected; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------|

|   | · | [***]  use      of the  [***] Intellectual Property is limited to use on      the  [***]  and  [***] ;  and |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | [***]  can      grant further licences of the  [***] Intellectual Property to      any third party, but may not do so in relation to      the  [***]  and the  [***]  . |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6 | The      Parties shall reasonably assist each other in defending themselves against      a Third Party claim which would impair the exploitation      of  [***]  Patent Rights,  [***]      Intellectual Property and/or  [***]  Intellectual      Property for the production of the Product.  Each Party shall      furnish the other with timely written notice of any and all infringements      and other unauthorized uses by any other person, firm, corporation or      other entity of any of  [***]  Patent      Rights,  [***] Intellectual Property or  [***]      Intellectual Property.  Furthermore, the Parties shall promptly      inform each other in the event either Party receives notice from any Third      Party or becomes otherwise aware that      the  [***]  Patent Rights, the  [***]      Intellectual Property or the  [***] Intellectual Property may      infringe Third Party IntellectualProperty. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.7 | In      relation only to      the  [***]  and  [***]  (and no      other product), to the extent that Lonza Technology (a) is incorporated      within the  [***]  or  [***] , or (b) has      been used in the manufacture of      the  [***]  or  [***] , Lonza hereby grants      Micromet, and Micromet hereby accepts      a  [***]  license under and to Lonza Technology, to      research, develop, have developed, conduct clinical trials for, formulate,      manufacture, have manufactured, test, seek regulatory approval for,      market, have marketed, commercialize, have commercialized, make, have      made, use, sell, have sold import, have imported and distribute and have      distributed  [***]  or  [***]      .  For the avoidance of doubt, the nature of the above licence      is as follows: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | Lonza’s      ownership of Lonza Technology is not affected, and except as set out in      item (iv) below,  [***] ; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | There      is no  [***]  toMicromet; |
|--------|------|----------------------------------------------------------|

|   | (iii) | Micromet’s      use of the Lonza Technology is limited to use on the Product and Modified      Product; and |
|--------|-------|-------------------------------------------------------------------------------------------------------------------|

----

|   | (iv) | Lonza      shall not  [***] in relation to the  [***] and      the  [***] . |
|--------|------|-----------------------------------------------------------------------------------------------------------|

| 9.  | Warranties      and Indemnification |
|----------|-------------------------------------|

| 9.1  | Lonza      warranty:  Lonza warrantsthat: |
|-----------|-----------------------------------------------------|

|   | (a) | the      Works and Services shall be performed in accordance with Clause      2; |
|--------|-----|----------------------------------------------------------------------------------|

|   | (b) | unencumbered      title (save for any Intellectual Property which may exist) to Product and      Results will be conveyed to Micromet upon  Delivery; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | on      the Effective Date the Lonza Technology is owned by Lonza or Lonza is      otherwise entitled to use it for the purposes of providing Works and      Services under this Agreement and during the term of this Agreement Lonza      shall not do or cause anything to be done which would adversely affect      their ownership or entitlement to use the same for those      purposes; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Lonza      has the necessary corporate authorisations to enter into this      Agreement; |
|--------|-----|------------------------------------------------------------------------------------------|

|   | (e) | on      the Effective Date and to the best of Lonza's knowledge and belief in the      context of absence of data regarding the Micromet Process, the estimated      timescales, dates for production, delivery etc., as set out in the Project      Plan, are realistic, provided, however,that Micromet      reasonably cooperates with Lonza and provides the permissions necessary to      progress, and Lonza has the resources available which are required to      perform the Works and Services in a timely  manner; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | on      the Effective Date and to the best of Lonza's knowledge and believe in the      context of absence of data regarding the Micromet Process, no additional      work is required to achieve theDeliverables; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | on      the Effective Date to the best of Lonza’s knowledge and belief, the use by      Lonza of the Lonza Process (excluding any modifications or steps made or      developed by Micromet, the Micromet Materials and Micromet Technology) and      Lonza Technology for the performance of the Works and Services as provided      herein will not infringe any rights (including without limitation any      intellectual or industrial property rights) vested in any Third Party      (provided, however,      that Micromet shall waive any breach of this warranty which arises      if a court of competent jurisdiction determines that the use by Lonza of      the Lonza Process, the Lonza Technology for the Works and Services      infringes the Intellectual Property of a Third Party, providedthat and for so long as      Lonza actually indemnifies Micromet pursuant to Clause 9.4      below); |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (h) | subject      to Clause 2.4, the Product will meet the  Specifications; |
|--------|-----|------------------------------------------------------------------------|

|   | (i) | Lonza      shall not use the Micromet Confidential Information, Micromet Materials,      the Micromet Technology, the Process and the  [***] Intellectual      Property for any purposes other than the Works and Services to be      performed for Micromet hereunder;and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (j) | Lonza      will notify Micromet in writing immediately if it receives or is notified      of a claim from a Third Party that the use by Lonza of the Process and/or      the Lonza Technology or  [***] Intellectual Property for Works      and Services infringes any Intellectual Property vested in such Third      Party. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.2  | Micromet      warranty:  Micromet warrants  that: |
|-----------|-------------------------------------------------------------|

|   | (a) | on      the Effective Date to the best of Micromet's knowledge and belief,      Micromet has the right to supply the Cell Line, the Micromet Process, the      other Micromet Materials and the Micromet Technology to Lonza and the      necessary rights to licence or permit Lonza to use the same for the      purpose of the Works and Services; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Micromet      has the necessary corporate authorisations to enter into this      Agreement; |
|--------|-----|---------------------------------------------------------------------------------------------|

|   | (c) | any      of the Cell Line, the Micromet Process, other Micromet Materials, and      Micromet Technology not owned by Micromet are licensed to Micromet under a      licence which will permit their use by Lonza to perform the Works and      Services; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Micromet      has the right to disclose the Micromet Confidential Information and to      allow the use of the Micromet Confidential Information by Lonza for the      purposes of and in accordance with the terms of this Agreement, and the      disclosure of the Micromet Confidential Information from Micromet to Lonza      and the use of such Micromet Confidential Information by Lonza in      accordance with the terms of this Agreement does not      constitute  [***] ; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | Micromet      has agreed to indemnify  [***]  regarding the transfer      of Micromet Technology and Micromet Materials and such indemnification      obligations correspond to (or go beyond) the obligations in Section 3.6 of      the  [***] ; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | on      the Effective Date and to the best of Micromet's knowledge and belief, the      timescales as set out in the Project Plan are realistic and Micromet will      be able to provide the Micromet Technology and the Micromet Materials to      perform the Works and Services in a timely  manner; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | on      the Effective Date and to the best of Micromet's knowledge and belief, no      additional work is required to achieve the  Deliverables; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (h) | on      the Effective Date and to the best of Micromet's knowledge and belief, the      use by Lonza of the Cell Line, the Micromet Process, other Micromet      Materials and the Micromet Technology for the Works and Services      (including without limitation the manufacture of the Product and excluding      any modifications or steps made or developed by Lonza and the Lonza      Technology) will not infringe any Intellectual Property of any Third Party      (provided, however,      that Lonza shall waive any breach of this warranty which arises if      a court of competent jurisdiction determines that the use by Lonza of the      Cell Line, other Micromet Materials or the Micromet Technology for the      Works and Services infringes the Intellectual Property of a Third Party,      provided that and      for so long as Micromet actually indemnifies Lonza pursuant to Clause 9.5      below); |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | the      Micromet Process had been used to manufacture Product in accordance with      cGMP and the Specifications; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------|

----

|   | (j) | Micromet      will promptly notify Lonza in writing if it receives or is notified of a      claim from a Third Party that the Cell Line, the Micromet Process, other      Micromet Materials, the Micromet Confidential Information, Micromet      Technology or that the use by Lonza thereof for the provision of the Works      and Services infringes any Intellectual Property of such Third      Party. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | For      the avoidance of doubt, Section 3.3 of      the  [***]  does in no way limit the warranties given      under this Clause 9.2. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.3 | Disclaimer:  THE      WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER      WARRANTIES, AND, EXCEPT FOR THE WARRANTIES EXPRESSLY SET FORTH IN THIS      AGREEMENT, ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY      DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY      OR FITNESS FOR A PARTICULARPURPOSE. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4 | Indemnification by      Lonza: Subject to Clause 9.6 below, Lonza shall defend,      indemnify and hold harmless each of Micromet, its Affiliates, and their      directors, officers, and employees and the successors and assigns of any      of the foregoing (each a "Micromet Indemnitee")      from and against any Third Party claims, actions, liabilities, costs and      expenses (including court costs and legal fees on a full indemnity basis)      that Micromet may suffer arising directly outof |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | any      breach of the warranties given by Lonza in Clause 9.1 above;      or |
|--------|-----|-------------------------------------------------------------------------------|

|   | (b) | any      claims alleging that Lonza’s use of the Lonza Process (i.e., claims which      do not allege that the Micromet Process is infringing), the Lonza      Technology and/or  [***] Intellectual Property (i.e., claims      which do not allege that the use of  [***]  and/or      the  [***]  is infringing) infringes any rights      (including without limitation any Intellectual Property) vested in a Third      Party (whether or not Lonza knows or ought to have known the same), provided that there      shall be excluded from this indemnity all Micromet revenue;    or |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | any      negligent or willful act or omission of Lonza in relation to the      Product. |
|--------|-----|-----------------------------------------------------------------------------------------|

| 9.5 | Indemnification by      Micromet:  Subject to Clause      9.6 below, Micromet shall defend, indemnify and hold harmless each of      Lonza, its Affiliates, and their directors, officers, and employees and      the successors and assigns of any of the foregoing (each a "Lonza Indemnitee") from      and against any Third Party claims, actions, liabilities, costs and      expenses (including court costs and legal fees on a full indemnity basis),      that Lonza may suffer arising directly outof |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | any      breach of the warranties given by Micromet in Clause 9.2 above;      or |
|--------|-----|----------------------------------------------------------------------------------|

|   | (b) | any      claims alleging Lonza’s use of the Cell Line, the Micromet Process, the      Micromet Materials or the Micromet Technology infringes any rights      (including, without limitation, any Intellectual Property) vested in any      Third Party (whether or not Micromet knows or ought to have known about      the same) provided      that there shall be excluded from this indemnity all Lonza actual      or potential revenues other than those which are an integral part of any      Price or fees which Micromet is obliged to pay to Lonza under this      Agreement; or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | any      negligent or wilful act or omission of Micromet in relation to the      Product; or |
|--------|-----|----------------------------------------------------------------------------------------------|

----

|   | (d) | any      claims raised by  [***]  against Lonza under Section      3.6 (b) and/or (c) of the  [***] , and any claims resulting from      an early termination of      the  [***]  by  [***] , provided that      Micromet is not required to indemnify Lonza of such claims under Clause      9.4 above. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.6 | Indemnification      Procedure: If a Lonza Indemnitee or Micromet Indemnitee (the      "Indemnitee")      intends to claim indemnification under this Clause 9, it shall promptly      notify the other Party (the "Indemnitor") in writing      of such alleged liability.  The Indemnitor shall have the right      to control the defence thereof with counsel of its choice as long as such      counsel is reasonably acceptable to Indemnitee; provided, however, that      any Indemnitee shall have the right to retain its own counsel at its own      expense, for any reason, including if representation of any Indemnitee by      the counsel retained by the Indemnitor would be inappropriate due to      actual or potential differing interests between such Indemnitee and any      other Party reasonably represented by such counsel in such      proceeding.  The Indemnitee, its employees and agents, shall      reasonably cooperate with the Indemnitor and its legal representatives in      the investigation of any liability covered by this Clause      9.  The obligations of this Clause 9.6 shall not apply to      amounts paid in settlement of any claim, demand, action or other      proceeding if such settlement is effected without the consent of the      Indemnitor, which consent shall not be withheld or delayed      unreasonably.  The failure to deliver written notice to the      Indemnitor within a reasonable time after the commencement of any such      action, if prejudicial to its ability to defend such action, shall relieve      the Indemnitor of any obligation to the Indemnitee under this Clause      9.  It is understood that only Lonza or Micromet may claim      indemnity under this Clause 9 (on its own behalf or on behalf of its      Indemnitees), and other Indemnitees may not directly claim indemnity      hereunder. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.7 | Disclaimer of Consequential      Damages:  Subject to the second sentence of this Clause      9.7, in no event shall either Party be liable to the other Party for      incidental, indirect, special, punitive or consequential damages arising      from or related to breach of this Agreement.  The foregoing      disclaimer of damages shall not apply in the case of (a) breach of Clause      10 (Confidentiality), (b) personal injury or death, or (c) grossly      negligent or intentionally wrongful acts or  omissions. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.8 | Limitation of      Liability:  Subject to clause 9.7 and to the second      sentence of this clause 9.8, in no event shall Lonza’s liability to      Micromet for direct damages arising from or related to breach of this      Agreement exceed the total maximum aggregate sum payable under this      Agreement by Micromet.  The foregoing limitation of liability      shall not apply in the case of (a) breach of clause 10 (Confidentiality),      (b) personal injury or death, or (c) negligent or intentionally wrongful      acts or omissions. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.9 | Insurance:  Lonza      and Micromet shall obtain and maintain during the term of this Agreement      and for  [***]  thereafter general liability insurance      with a reputable and solvent insurance provider in the amount      of  [***]  per event or linked events.  Such      general liability insurance shall insure against all mandatory liability      including liability for personal injury, physical injury and property      damage.  The Parties shall provide each other with written proof      of the existence of such insurance uponrequest. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.10 | [***] :  In      order to execute this Agreement, Micromet has required Lonza to enter into      the  [***] .  Micromet acknowledges and agrees that      Lonza has no liability to Micromet under this Agreement or otherwise,      should any action or step be taken by  [***]  and/or      Lonza in compliance with the  [***].. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.  | Confidentiality |
|-----------|-----------------|

| 10.1 | Micromet      acknowledges that Lonza Confidential Information, and Lonza acknowledges      that Micromet Confidential Information (jointly the "Confidential      Information") with which they are supplied by the other pursuant to      the Agreement are supplied, subject to Clause 10.5, in circumstances      imparting an obligation of confidence and each agrees to keep such      Confidential Information secret and confidential and to respect the      other's proprietary rights therein and not at any time for any reason      whatsoever to disclose or permit such Confidential Information to be      disclosed to any Third Party save as expressly provided      herein. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | Micromet      and Lonza shall each procure that all their respective employees,      consultants, contractors and persons for whom it is responsible having      access to Lonza Confidential Information or Micromet Confidential      Information shall be subject to the same obligations of confidence as the      principals pursuant to Clauses 10.1 and 10.3 and shall be bound by secrecy      agreements in support of suchobligations. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | Lonza      and Micromet each undertake not to disclose or permit to be disclosed to      any Third Party other than to those of its officers, employees, agents,      consultants, licensees and financial investors that have a need to know      the Confidential Information of the disclosing Party for purposes of this      Agreement, provided      that such disclosure will be made under a confidentiality      non-disclosure agreement comprising of terms at least as stringent as the      confidentiality provisions under this Clause 10.  Furthermore,      Micromet will be entitled to disclose the Process and the terms and      conditions of this Agreement to (i) potential licensees or collaboration      partners regarding the Product, and to (ii) potential acquirers of      Micromet, provided,      however, that such potential licensees, collaboration partners or      acquirers are in an advanced due diligence stage, that such disclosure is      necessary to evaluate the respective project, that such potential licensee      or collaboration partner is one of the fifty (50) leading pharmaceutical      companies in the world, based on annual sales, and has its headquarters in      the permitted territories listed in Schedule 12      (but may not be disclosed to Affiliates outside these permitted      territories) and that such disclosure will be made under a confidentiality      non-disclosure agreement comprising of terms at least as stringent as the      confidentiality provisions under this Clause 10.  With respect      to any other potential licensees, collaboration partners and acquirers      disclosure can only be made upon Lonza's prior written consent, such      consent not to be unreasonably withheld or delayed.  The Parties      shall take responsibility for any infringement of confidentiality by any      Third Party to which the receiving Party discloses Confidential      Information of the disclosingParty. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4 | Notwithstanding      Clause 10.3, Lonza and Micromet each undertake not to otherwise make use      of or permit to be made use of the Confidential Information of the other      Party or except to the extent that the same is required to be disclosed      pursuant to subpoena, court order, judicial process or otherwise by law,      provided that the      receiving Party provides prompt notice to the disclosing Party of such      requirement in order to give the disclosing Party an opportunity to timely      seek a protective order or other appropriate judicial      relief.  In the event the disclosing Party is unable to obtain a      protective order or other appropriate judicial relief, the receiving Party      shall disclose only that portion of the disclosing Party’s Confidential      Information which is legally required to be disclosed, and ensure that all      such Confidential Information of the disclosing Party shall be redacted to      the fullest extent permitted by law prior to such disclosure and that the      disclosing Party shall be given an opportunity to review the Confidential      Information prior to itsdisclosure. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.5 | The      obligations of confidence referred to in this Clause 10 shall not extend      to any information for which the receiving Party can prove by written      evidence that: |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | it      was or became generally available to the public otherwise than by reason      of a breach by the receiving Party of the provisions of this Clause      10; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | it      was known to the receiving Party and is at its free disposal prior to its      receipt from the disclosing Party; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------|

|   | (c) | it      was subsequently disclosed to the receiving Party without being made      subject to an obligation of confidence by a Third  Party; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Lonza      or Micromet are required to disclose under any statutory, regulatory or      similar legislative requirement, subject to the imposition of obligations      of secrecy wherever possible in that relation;  or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | it      was developed by any servant or agent of the receiving Party without      access to or use or knowledge of the information by the disclosing      Party. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.6  | The      Parties acknowledges that: |
|------------|-------------------------------------|

|   | (a) | without      prejudice to any other rights and remedies that the Parties may have, the      Parties agree that the Lonza Confidential Information and Micromet      Confidential Information is valuable and that damages may not be an      adequate remedy for any breach of the provisions of this Clause      10.  The Parties agree that the relevant Party will be entitled      without proof of special damage to seek the remedies of an injunction and      other equitable relief for any actual or threatened breach by the other      Party; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | save      as provided herein Lonza shall not at any time have any right, title,      licence or interest in or to the Micromet Technology or any other      Intellectual Property vested in Micromet or to which Micromet is entitled;      and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | save      as provided herein Micromet shall not at any time have any right, title,      licence or interest in or to Lonza Confidential Information, the Lonza      Technology or any other Intellectual Property relating to the Process      which are vested in Lonza or to which Lonza is otherwise      entitled. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.7 | All      Confidential Information is and shall remain the sole and exclusive      property of the disclosing Party.  The receiving Party agrees      that upon termination of this Agreement and subject to Micromet's right to      retain certain Confidential Information under the Technology Transfer and      License Agreement, within  [***]  thereafter, the      receiving Party shall:  (a) cease any use of the Confidential      Information, including any  [***] , and all copies of the      foregoing or any portion thereof, in whatever form or medium stored, and      (b) transfer all Confidential Information of the disclosing Party,      including all documents, samples, summaries, extracts, records or other      materials that contain any Confidential Information, in whatever form or      medium stored, to the disclosing Party or its designee, and such designee      shall be subject to legally binding nondisclosure and use restrictions      that are at least as restrictive as the terms of this Agreement, and (c)      upon completion of such transfer, certify in writing that such transfer is      complete. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.  | Option      for  [***] |
|-----------|----------------------------------|

| 11.1 | Lonza      hereby grants to Micromet an option to conclude      a  [***]  for the  [***] .  The      terms and conditions of such  [***]  shall be      negotiated in good faith and based on the conditions provided in Schedule      13.  On a regular basis during the term of this      Agreement, Lonza will inform Micromet about the lead times for      reservations of slots for the  [***]  and the Parties      will agree on any reasonable updates to Schedule 13, such first update to      be agreed after establishment of the Process at  Lonza. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2 | Due      to the need of  [***] , Micromet will  [***]      for  [***] at the latest  [***] prior to      the  [***] of  [***] .  In the event that      such  [***]  is not concluded before regulatory      approval for the Product is granted, Micromet's option under this Clause      11 will expire. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.  | Termination      of the Agreement, Termination of Certain Works and Services or      Slots |
|-----------|--------------------------------------------------------------------------------------------|

| 12.1 | This      Agreement shall commence on the Effective Date and shall expire upon      completion of the Works and Services, unless earlier terminated in      accordance with this Clause 12. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2 | If      it becomes apparent to either Lonza or Micromet at any stage in the      provision of the Works and Services that it will not be possible to      complete the Works and Services for scientific or technical reasons, such      issue shall be discussed in the Steering Committee and      a  [***]  period shall be allowed for good faith      discussion and attempts to resolve such problems or to agree on a mutual      termination of this Agreement. If such problems are not resolved within      such period, Micromet shall be entitled to terminate the Agreement      forthwith by notice in writing and with immediate      effect.  Furthermore, Micromet may in its sole discretion      terminate this Agreement in whole or terminate certain Works and Services      or production slots of the Project Plan at any time for any reason by      giving not less than  [***]  notice in writing to      Lonza.  In the event of any such termination outlined above,      Micromet shall pay to Lonza a termination sum calculated by reference to      all the Works and Services performed by Lonza prior to such termination      (including a pro rata proportion of the Price for any stage of the Works      and Services which is in process at the date of termination) and all      expenses reasonably incurred by Lonza in giving effect to such      termination, including the costs of terminating any commitments entered      into under the Agreement, provided, however, that      Lonza will make all reasonable efforts to use any materials and services      intended for Micromet for other purposes.  The termination sum      shall not exceed the unpaid Price for the stage in process and any prior      stages and no re-imbursement to Lonza is owed by Micromet in the event      notice to terminate Works and Services pursuant to this Clause 12.2 is      issued to Lonza more than  [***]  before Lonza's then      estimated start date for any stage. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.3 | In      the event of termination pursuant to Clause 12.2 and subject to Clauses      12.5, 12.6 and 12.7 Micromet shall pay Lonza a termination sum regarding      terminated production slots calculated in accordance with the principles      of Clause 12.2 above plus: |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | in      the event notice to terminate Works and Services pursuant to this Clause      12.3 is issued to Lonza  [***]  or less before Lonza’s      then estimated start date for any stage of those Works and Services which      include activities in Lonza’s cGMP fermentation and/or purification      facilities (i.e., the cGMP Batches), or is issued to Lonza at any time      during any such stage, Micromet shall pay Lonza a sum equal      to  [***]   [***] , which payment to Lonza shall      become due on the date of termination of such Works and Services;      or |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (b) | in      the event notice to terminate Works and Services pursuant to this Clause      12.3 is issued to Lonza more than  [***]  but not more      than  [***]  before Lonza’s then estimated start date      for any stage of those Works and Services which include activities in      Lonza’s cGMP fermentation and/or purification facilities (i.e. the cGMP      Batches), Micromet shall pay Lonza a sum equal      to  [***]   [***] ; which payment to Lonza shall      become due on the date of termination of such Works and Services;      or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | in      the event notice to terminate Works and Services pursuant to this Clause      12.3 is issued to Lonza more than  [***]  but not more      than  [***]  months before Lonza’s then estimated      start date for any stage of those Works and Services which include      activities in Lonza’s cGMP fermentation and/or purification facilities      (i.e. the cGMP Batches), Micromet shall pay Lonza a sum equal      to  [***]   [***] ; which payment to Lonza shall      become due on the date of termination of such Works and      Services. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The      price of the  [***]  shall not include      the  [***] .  Any  [***]  ordered      at the time of termination which cannot be used by Lonza for other      purposes will be paid by Micromet and Micromet may request transfer of      such  [***]  toMicromet. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | No      re-imbursement to Lonza is owed by Micromet in the event notice to      terminate Works and Services pursuant to this Clause 12.3 is issued to      Lonza more than  [***]  months before Lonza's then      estimated start date for any Batch.  Furthermore and for the      avoidance of doubt, no re-imbursement to Lonza is owed by Micromet in the      event a  [***] is  [***] but has to  [***]      to  [***] to a  [***] in the  [***] of      the  [***] , unless such  [***] is      subsequently  [***] |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4 | Lonza      shall use commercially reasonable efforts to otherwise use any capacities      and  [***] fully or partly, which have been  [***]      for  [***] and which are  [***] to      the  [***] of certain  [***] and  [***] or      the  [***]   The obligation to make payment under      Clause12.3 shall be reduced (retrospectively, and hence Lonza shall make      an appropriate refund to Micromet) to the extent that Lonza mitigates its      loss in this regard (and Lonza shall promptly notify Micromet of any such      mitigation).  This provision shall not entitle Micromet to be      refunded an amount greater than that paid by Micromet to Lonza pursuant to      this Clause 12 and Lonza shall be entitled to deduct from the amount due      to be refunded to Micromet its reasonable personnel and associated costs      in attempting to mitigate its loss. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5 | For      the avoidance of doubt activities relating to cGMP fermentation shall be      deemed to commence with the date of removal of the vial of cells from      frozen storage for the performance of the  fermentation. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.6 | The      Parties may each terminate the Agreement forthwith by notice in writing to      the other Party if the other commits a material breach of the Agreement      (which shall include a breach of the warranties set out in Clause 9 above)      which in the case of a breach capable of remedy is not remedied      within  [***]  in the event of a breach of payment      obligations, and within  [***]  in the event of any      other breach, of the receipt by the other of notice identifying the breach      and requiring its remedy. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7 | Micromet      may terminate this Agreement forthwith by notice in writing to Lonza upon      the occurrence of any of the followingevents: |
|------|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Lonza      is unable  [***] set forth in  [***] and      incurs  [***] for reasons other than  [***]      the  [***] and/or the  [***] or  [***] in      accordance with this Agreement; or |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  |  [***] (b) | the      use of  [***] for the manufacture of Product [***] provided, however,      that  [***] pay the termination fees under Clauses 12.2      and 12.3 above if at  [***] that the [***] ; or [***] (c)Lonza  [***]      or  [***] of the  [***] or  [***]      . |
|--|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.8  | Upon      the termination of this Agreement for whatever  reason: |
|------------|-------------------------------------------------------------------|

|   | (a) | Lonza      shall promptly return to Micromet all Micromet Know How and shall dispose      of or return to Micromet the Micromet Materials, the Micromet Cell Line      and the Micromet Process and any materials therefrom, as directed by      Micromet; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Micromet      shall promptly return to Lonza all Lonza Confidential Information it has      received from Lonza; |
|--------|-----|------------------------------------------------------------------------------------------------------------------|

|   | (c) | Lonza      shall summarize all Works and Services performed up to the termination of      the Agreement and provide such summary documents to    Micromet; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | subject      to Clause 14 below, Micromet shall not thereafter use or exploit the Lonza      Technology in any way whatsoever;and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | Lonza      and Micromet shall do all such acts and things and shall sign and execute      all such deeds and documents as the other may reasonably require to      evidence compliance with this Clause12.8. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.9 | Termination      of this Agreement for whatever reason shall not affect the accrued rights      of either Lonza or Micromet arising under or out of this Agreement and all      provisions which are expressed to survive the Agreement shall remain in      full force and effect. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.  | [***] |
|-----------|-------|

|   | (a) | engage      in, continue in or carry on [***] any  [***] of  [***]      which contain the same  [***]  as      the  [***]  or  [***] ,      including  [***] any  [***] in      any  [***]  or other form      of  [***]  which is so  engaged; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | consult      with, advise or assist in any way, whether or not for consideration, any      corporation or other business organization which  [***]      or  [***] containing the same  [***]  as      the  [***]  or  [***]  ; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | engage      in any practice the purpose of which is to evade the provisions of      this  [***] ; |
|--------|-----|-------------------------------------------------------------------------------------------------------------|

|   | provided, however, that      the foregoing prohibition does not extend      to  [***]  of the  [***]  of      the  [***] . |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.  | Technology      Transfer and License |
|-----------|--------------------------------------|

|   | At      any time during the course of this Agreement and  [***] (except      in the case of  [***] , Micromet has the option to conclude the      Technology Transfer and License Agreement between Micromet and Lonza      attached hereto as Schedule 14, in      order to allow Micromet (or a Third Party designated by Micromet) to      replicate the Process (as it exists at the date of such request) in the      manufacture of the Product in order to either establish a second source      for supply or to transfer manufacturing to a Third Party, provided, however, that      if Micromet is or has been in insolvency proceedings at the time Micromet      [***] under this Clause 14, it shall  [***] if  [***]      by  [***] and/or other  [***] which      are  [***] and operating, with respect of      the  [***]  of the  [***] (but not      by  [***] ,  [***] and/or other  [***]      ).  Following exercise of the option and      provided  [***]  of Lonza have been used for the      manufacture of Product, Lonza shall supply to Micromet such information      and assist Micromet regarding access to  [***]      and  [***] , as is agreedtherein. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 15.  | Force      Majeure |
|-----------|--------------------|

| 15.1 | If      Lonza is prevented or delayed in the performance of any of its obligations      under the Agreement by Force Majeure and shall give written notice thereof      to Micromet specifying the matters constituting Force Majeure together      with such evidence as Lonza reasonably can give and specifying the period      for which it is estimated that such prevention or delay will continue,      Lonza shall be excused from the performance or the punctual performance of      such obligations as the case may be from the date of such notice for so      long as such cause of prevention or delay shall  continue. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.2 | The      expression "Force      Majeure" shall be deemed to include any cause affecting the      performance by Lonza of the Agreement arising from or attributable to      acts, events, acts of God, omissions or accidents beyond the reasonable      control of Lonza. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.  | Governing      Law, Jurisdiction andEnforceability |
|-----------|----------------------------------------------------|

| 16.1 | The      construction, validity and performance of the Agreement shall be governed      by the laws of Switzerland. |
|------|---------------------------------------------------------------------------------------------------------------------|

| 16.2 | No      failure or delay on the part of either Lonza or Micromet to exercise or      enforce any rights conferred on it by the Agreement shall be construed or      operate as a waiver thereof nor shall any single or partial exercise of      any right, power or privilege or further exercise thereof operate so as to      bar the exercise or enforcement thereof at any time or times      thereafter. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.3 | Any      disputes relating to issues arising from this Agreement shall, in the      absence of resolution within  [***]  of the dispute      arising, be referred to the  [***]  of Micromet and      Lonza, who shall discuss the matter and attempt to resolve it by mutual      consent.  The  [***]  of Micromet and Lonza      shall meet once face-to-face within  [***]  to discuss      and resolve the dispute.  If the dispute cannot be resolved      within  [***] , either Party may, by written notice to the other      Party, invoke the mediation procedure set out in Clause 16.4      below. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.4 | If      a dispute arises between the Parties that the Parties cannot resolve      pursuant to Clause 16.3 above, the Parties agree to try to solve such      dispute amicably by mediation.  The Parties shall conduct a      mediation procedure according to the ICC ADR Rules of the International      Chamber of Commerce (ICC) in effect on the date of the commencement of the      mediation proceedings.  The location of the mediation      proceedings will be Basel. The number of mediators will be one      (1).  The language of the mediation proceeding will be      English.  If the dispute has not been settled pursuant to the      said rules within  [***]  following the filing of a      request for mediation or within such other period as the Parties may agree      in writing, either Party may submit the dispute to final and binding      arbitration. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 16.5 | Any      dispute relating to the validity, performance, construction or      interpretation of this Agreement, which cannot be resolved amicably      between the Parties, shall be submitted to arbitration in accordance with      the ICC Arbitration Rules of the International Chamber of      Commerce.  The decision of the arbitrators shall be final and      binding upon the Parties (absent manifest error on the part of the      arbitrator(s)) and enforceable in any court of competent      jurisdiction.  The location of arbitration will be      Basel.  The arbitration will be heard and determined by one (1)      arbitrator, who will be jointly selected by Lonza and      Micromet.  If, within  [***]  following the      date upon which a claim is received by the respondent, the Parties cannot      agree on a single arbitrator, the arbitration will be heard and determined      by three (3) arbitrators, with one arbitrator being appointed by each      Party and the third arbitrator being selected by the two Party-appointed      arbitrators.  If either Party fails to select an arbitrator, or      if the Party-appointed arbitrators cannot agree on a third arbitrator      within  [***]  of the respondent receiving the claim,      such arbitrator will be appointed by the International Court of      Arbitration according to the ICC Rules.  The arbitration award      that is consistent with the provisions of this Agreement that is so given      will be binding upon the Parties, accompanied by a reasoned opinion in      writing (in English), and the judgment on the award may be entered in any      court having competent jurisdiction thereof.  Each Party will      bear its own costs and expenses (including its attorney’s fees) associated      with any arbitration initiated under this section, and each Party will      bear an equal share of the arbitrators’ and administrative fees associated      with any arbitration initiated under this section.  The language      of the arbitration proceeding will be English.  Notwithstanding      the provisions of this Clause 16.5, each Party shall have the right to      seek preliminary or permanent injunctive or other equitable relief in any      court of competent jurisdiction as such Party deems necessary to preserve      its rights and to protect itsinterests. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 16.6 | Nothing      in this Clause 16 shall prevent a Party from exercising any right under      this Agreement, including the right of termination under Clause 12      above. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 17.  | Notices |
|-----------|---------|

| 17.1 | Any      notice or other communication to be given under this Agreement shall be      delivered personally or sent by facsimile transmission, or if facsimile      transmission is not available, by first class pre-paid post addressed as      follows: |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)    | If      to Lonza to: | Lonza      Sales AG                                   |
|--------|----------------------|-------------------------------------------------------|
|   |                 | Muenchensteinerstrasse      38                        |
|   |                 | CH-4402      Basel                                    |
|   |                 | Switzerland                                           |
|   |                 | Facsimile:      +41 61 316 8329                       |
|   |                 | Attention:      The Head of Legal Services            |
|   |                 |                                                  |
|   | with      a copy to: | Lonza      Biologics plc                              |
|   |                 | 228      Bath Road                                    |
|   |                 | Slough                                                |
|   |                 | Berkshire      SL1 4DX                                |
|   |                 | England                                               |
|   |                 | Facsimile:      +44 1753 777001                       |
|   |                 | Attention:  The      Head of Legal Services |

----

| (b)    | If      to Micromet to: | Micromet      AG                             |
|--------|-------------------------|----------------------------------------------|
|   |                    | Staffelseestrasse      2                     |
|   |                    | D-81477      Munich                          |
|   |                    | Germany                                      |
|   |                    | Facsimile:      +49-89-895 277 205           |
|   |                    | Attention:      Head of Business Development |
|   |                    |                                         |
|   | with      a copy to:    | Micromet,      Inc.                          |
|   |                    | 6707      Democracy Boulevard                |
|   |                    | Suite      505                               |
|   |                    | Bethesda,      MD 20817                      |
|   |                    | United      States of America                |
|   |                    | Attention:      General Counsel              |
|   |                    | Facsimile:      +1 240 752-1425              |

| 17.2  | All      such notices or other communications shall be deemed to have been served      as follows: |
|------------|----------------------------------------------------------------------------------------------------|

|   | (a) | if      delivered personally, at the time of such  delivery; |
|--------|-----|--------------------------------------------------------------|

|   | (b) | if      sent by facsimile, upon receipt of the transmission confirmation slip      showing completion of thetransmission; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------|

|   | (c) | if      sent by first class pre-paid post, ten (10) business days (Saturdays,      Sundays and Bank or other public holidays excluded) after being placed in      the post. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.  | Illegality |
|-----------|------------|

| 18.1 | If      any provision or term of this Agreement or any part thereof shall become      or be declared illegal, invalid or unenforceable for any reason whatsoever      including but without limitation by reason of the provisions of any      legislation or other provisions having the force of law or by reason of      any decision of any Court or other body or authority having jurisdiction      over the Parties hereto or this Agreement including the EC Commission or      the European Court of Justice: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | such      provision shall, so far as it is illegal, invalid or unenforceable, be      given no effect by the Parties and shall be deemed not to be included in      this Agreement; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | the      other provisions of this Agreement shall be binding on the Parties as if      such provision was not included therein;and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | the      Parties agree to negotiate in good faith to amend such provision to the      extent possible for incorporation herein in such reasonable manner as most      closely achieves the intention of the Parties without rending such      provision invalid or unenforceable. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 19.  | Quality      Agreement |
|-----------|------------------------|

|   | Simultaneously      with the execution of this Agreement, the Parties will enter into a      separate quality agreement as annexed hereto as Schedule 10      ("Quality      Agreement").  The Quality Agreement and its Exhibits      supplement this Agreement.  To the extent that inconsistencies      exist between the contents of the Quality Agreement and this Agreement,      the stipulations of this Agreement shall  prevail. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 20.  | Miscellaneous |
|-----------|---------------|

| 20.1 | Lonza      shall be entitled to instruct one or more of its Affiliates to perform any      of Lonza’s obligations contained in this Agreement, but Lonza shall remain      fully responsible in respect of those obligations.  Subject      thereto, neither Party shall be entitled to assign, transfer, charge or in      any way make over the benefit and/or the burden of this Agreement without      the prior written consent of the other which consent shall not be      unreasonably withheld or delayed, save that either Party shall be entitled      without the prior written consent of the other Party to assign, transfer,      charge, sub-contract, deal with or in any other manner make over the      benefit and/or burden of this Agreement to a successor of that Party’s      business by reason of merger, sale or license of all or substantially all      of its assets related to this Agreement or any other form of      acquisition. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.2 | The      obligations of the Parties under Clauses 8 (Intellectual Property), 9      (Warranties and Indemnification), 10 (Confidentiality), and 12.8 and 12.9      (consequences of termination) and 14 (Technology Transfer and License)      shall survive the termination of this Agreement for any      reason. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.3 | The      press releases that Micromet and Lonza will issue upon execution of this      Agreement are attached hereto as Schedule      15.  The text of any further press release or other      further communication to be published by or in the media concerning the      subject matter of the Agreement shall require the prior written approval      of Lonza and Micromet. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.4 | The      Agreement embodies the entire understanding of Lonza and Micromet and      there are no promises, terms, conditions or obligations, oral or written,      expressed on implied, other than those contained in the      Agreement.  The terms of the Agreement shall supersede all      previous agreements (if any) which may exist or have existed between Lonza      and Micromet relating to the Works andServices. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.5 | The      Parties to this Agreement do not intend that any term hereof should be      enforceable by any person who is not a Party to this      Agreement. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 20.6 | No      variation of or addition to this Agreement or any part thereof shall be      effective unless in writing and signed on behalf of both      Parties.  Notwithstanding the above the Parties hereby confirm      that amendments to the Specifications shall be effective if reduced to      writing and signed by the quality and/or regulatory representative of both      Parties, which quality and/or regulatory representative shall be nominated      from time to time by each Party. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Schedule      1: |   | Micromet      Materials including Cell Line Particulars |
|------------------|--------|---------------------------------------------------------|
| Schedule      2: |   | Product      Specifications                             |
| Schedule      3: |   | Prices      and Terms of Payment                        |
| Schedule      4: |   | Identification      of Lonza Know How                   |
| Schedule      5: |   | List      of Lonza PatentRights                         |

----

| Schedule      6:   |   | Identification      of Micromet Know-How           |
|--------------------|--------|----------------------------------------------------|
| Schedule      7:   |   | List      of Micromet Patent Rights                |
| Schedule      8 A: |   | Project      Plan up to Stage 30                   |
| Schedule      8 B: |   | Project      Plan for pre-LA (as of Stage 31)      |
| Schedule      9:   |   |  [***]  Agreement                   |
| Schedule      10:  |   | Quality      Agreement                             |
| Schedule      11:  |   | Testing      of Product                            |
| Schedule      12:  |   | Territories                                        |
| Schedule      13:  |   | Terms      and Conditions for  [***]     |
| Schedule      14:  |   | Technology      Transfer and License Agreement     |
| Schedule      15:  |   | Micromet      Press Release and Lonza PressRelease |

| Micromet      AG   |                             | Lonza      Sales AG |
|--------------------|----------------------------------|---------------------|
|               |                             |                |   |   |
| Signature:         | /s/ Jens Hennecke                |                | Signature: | /s/ Una Hultry |
| Printed Name: | Jens Hennecke                    |                | Printed Name: | Una Hultry |
| Title:             | SVP Business Development         |                | Title: | Authorized Signatory |
|               |                             |                |   |   |
| Signature:         | /s/ Patrick Baeuerle             |                | Signature: | /s/ Gerry Kennedy |
| Printed      Name: | Patrick Baeuerle                 |                | Printed      Name: | Gerry Kennedy |
| Title:             | SVP, Chief Scientific    Officer |                | Title: | Authorized  Signatory |

----

----

----

----

----

----

----

| ApplicationNumber |   | ApplicationFiling Date |   |   | Country |   |   | Title of Application |   |   | Status |   |   | Patent Number |   |
|-------------------|--------|-----------------------------|--------|--------|---------|--------|--------|--------------------------------|--------|--------|--------|--------|--------|--------------------|--------|
|              |   |                        |   |   |    |   |   |                           |   |   |   |   |   |               |   |   |   |   |   |   |

----

----

----

----

----

----

----

| 1. | LONZA SALES AG, of      Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter      referred to as "Lonza")    and |
|----|---------------------------------------------------------------------------------------------------------------------------------|

| 2. | MICROMET AG, of      Staffelstrasse 2, D-81477, Munich, Germany (hereinafter referred to as      "Micromet") |
|----|--------------------------------------------------------------------------------------------------------------|

| A | Lonza      and Micromet have entered into a Development and Supply Agreement pursuant      to which Lonza agreed to provide Micromet with development, manufacturing      and supply services ("Works and Services") for      Micromet's Intermediate Biological (Investigational) Medicinal Product      (IB(I)MP) MT103 (also known as Blinatumomab) for use as proprietary      investigational medicinal product (the "Product"). |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | The      Parties now wish to further define the pharmaceutical roles and      responsibilities of each Party for the Manufacture, testing and Release of      Product with respect to relevant current Good Manufacturing Practices      ("cGMP") and      Applicable Laws. Nothing in this Quality Agreement shall limit a Party’s      obligation to comply with cGMP and Applicable Laws (as defined below) on      the occasion that Lonza Manufactures Product for Micromet for further      manufacturing use in the preparation of human drug products for clinical      trial supply. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C | This      Quality Agreement takes the form of a detailed checklist of the activities      associated with the production, analysis, release, and distribution of      Product. Responsibility for each activity is assigned to either Lonza      and/or Micromet in the appropriate box in the delegation responsibility      checklist that follows. To facilitate routine communications between the      Parties, a list of key contacts is provided in Annex 1. For each      responsibility listed, the respective Party is required to put into effect      all applicable procedures and to take all necessary actions to execute      that responsibility in accordance with cGMP and Applicable      Laws. |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D. | The      Parties wish that Lonza, having particular expertise in the activities      contained in this Quality Agreement (as defined below), may perform the      activities and obligations set forth in this Quality      Agreement. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.     | Preface      / Overall Responsibilities                                                          | 4                                                      |
|--------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| 2.     | Definitions      and Interpretation                                                              | 5                                                      |
| 3.     | Facilities      / Materials Controls                                                             | 8                                                      |
|   | 3.1                                                                                              | Organization      and Key Personnel                    | 8 |
|   | 3.2                                                                                              | Buildings,      Facilities, Utilities and Equipment    | 9 |
|   | 3.3                                                                                              | Raw      Materials Controls                            | 10 |
| 4.     | Process      Controls                                                                            | 11                                                     |
|   | 4.1                                                                                              | Cell      Banks                                        | 11 |
|   | 4.2                                                                                              | Product      Specification                             | 11 |
|   | 4.3                                                                                              | Production,      Process Handling and Process Control  | 11 |
|   | 4.4                                                                                              | Product      Storage, Labeling, Packaging and Shipment | 13 |
| 5.     | Quality      Control Laboratories                                                                | 13                                                     |
|   | 5.1                                                                                              | QC      Laboratory Controls                            | 13 |
| 6.     | Quality      Assurance / Quality Management Systems                                              | 15                                                     |
|   | 6.1                                                                                              | Complaints,      Recalls and Adverse Events            | 15 |
|   | 6.2                                                                                              | Batch      Review and Product Disposition              | 16 |
|   | 6.3                                                                                              | Records      Retention                                 | 16 |
|   | 6.4                                                                                              | Deviations      / Investigation Reports                | 17 |
|   | 6.5                                                                                              | Change      Control Procedures                         | 17 |
| 7.     | Regulatory      Authorizations and Inspections                                                   | 18                                                     |
|   | 7.1                                                                                              | Regulatory      Agency Inspections                     | 18 |
|   | 7.2                                                                                              | Regulatory      Authorizations / Submissions           | 18 |
| 8.     | Micromet      Oversight                                                                          | 19                                                     |
|   | 8.1                                                                                              | Audit      Allowance                                   | 19 |
|   | 8.2                                                                                              | Periodic      Review of Quality Agreement              | 20 |
| 9.     | Term                                                                                             | 21                                                     |
| 10.    | Miscellaneous                                                                                    | 21                                                     |
|   | Annex      1 - Key Contacts                                                                      | 23                                                     |
|   | Annex      2 - Multi Site Responsibilities Matrix                                                | 24                                                     |
|   | Annex      3 - Additional Considerations  for IB(I)MP Intended for      Commercial Use | 25                                                     |
|   | Annex      4 - Information to be provided to Micromet                                            | 26                                                     |

----

| 1.  | Preface      / Overall Responsibilities |
|----------|-----------------------------------------|

| 1.1 | This      Quality Agreement outlines the responsibilities of Micromet and Lonza with      respect to the quality assurance of Product Manufactured by Lonza for      Micromet under the terms of the Development and Supply Agreement and in      accordance with cGMP and ApplicableLaws. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2 | Micromet      acknowledges that certain activities and obligations under the Quality      Agreement may be performed by Lonza’s Affiliates having expertise in the      relevant areas, provided that (i) Lonza shall remain responsible to      Micromet for the acts and omissions of their Affiliates; and (ii) Micromet      is at any time informed which of Lonza's Affiliates is in charge of that      certain activities and obligations. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3 | The      following delegation responsibility checklist describes generic quality      activities that are to be performed by both Parties for Product used by      Micromet for further manufacturing use in the preparation of human drug      products for clinical trial supply / in market supply.  The      specific Works and Services to be provided by Lonza are set out in the      Development and Supply Agreement (and any amendments to the Development      and Supply Agreement) on Price and other terms accepted by both      Parties. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.4 | Lonza      is responsible for ensuring that the quality requirements for Product are      as specified in the approved Product Specification and that Product is      Manufactured in accordance with cGMP and all Applicable    Laws. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.5 | Lonza      is responsible for final review, approval and QP certification of the      Product for further processing. |
|-----|-----------------------------------------------------------------------------------------------------------------------|

| 1.6 | LONZA      is responsible for analytical testing of the Product and the further      processed Drug Product. |
|-----|--------------------------------------------------------------------------------------------------------------|

| 1.7 | Micromet      or its designee is responsible for shipping and the final review, approval      and Release of the final Drug Product for use in clinical trial      supply. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.  | Definitions      and Interpretation |
|----------|-------------------------------------|

|   | Applicable      Laws | means      all applicable provisions of all statutes, laws, rules, regulations,      administrative codes, permits and licenses from regulatory authorities or      agencies applicable to the Manufacture of the  Product; |
|--------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Batch | means      the total Product (Drug Substance) obtained from the fermentation and      associated purification using the Process and carried out in accordance      with cGMP and Applicable Laws; |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Batch      Records | means      the completed documentation associated with the manufactured Product on      each Batch for official and cGMP compliant documentation      purposes; |
|--------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Certification | means      a certification of any Batch by a Qualified Person for further processing      confirming that the Batch is manufactured in accordance with the relevant      requirements for human use (as defined in Directive 2001/83/EC for      medicinal products for human use), commonly known as “QP batch      release”; |
|--------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | CofA | means      Certificate of Analysis; |
|--------|------|-------------------------------------|

|   | CofC | means      Certificate of Compliance; |
|--------|------|---------------------------------------|

|   | cGMP | means      current Good Manufacturing Practice and general biologics products      standards as promulgated under the European Commission Directives      91/356/EEC, as amended by Directive 2003/94/EC, and 91/412EEC      respectively; the International Committee for Harmonisation (ICH) Q7      Guideline on Good Manufacturing Practice for Active Pharmaceutical      Ingredients; the U.S. Federal Food, Drug and Cosmetic Act found in Title      21 of the U.S. Code of Federal Regulations (CFR), including but not      limited to Parts 210, 211 and Parts 11, 310 et seq., 600 to 610, the      European Commission Guidelines of Good Manufacturing Practices for      Medicinal Products as promulgated under European Directive 2003/94/EC      (Eudralex – Volume IV) and the respective Japanese directives and      guidelines by the Japanese authorities, as applicable. Lonza meets EU GMP      requirements as defined in Eudralex - Volume IV Good Manufacturing      Guidelines by the European Commission for medicinal products for human and      veterinary use (EU-GMP Guidelines); |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Development and Supply      Agreement | means      the Development and Supply Agreement to which this      Quality Agreement is attached as Schedule  10; |
|--------|---------------------------------------|-------------------------------------------------------------------------------------------------------------------|

|   | Drug    Product | Product      or a combination of Product with other substances being in its final      container suitable for administration to human beings (bulk unlabeled and      final product labeled). |
|--------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | Drug Product      Specification | means      the specification for Drug Product, set forth under Sections B and C of      Schedule 2 of the Development and Supply Agreement, and any amendments to      any of the foregoing specifications regarding the Drug Product as agreed      upon by the Parties from time totime; |
|--|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Facility/      Facilities | means      the facilities of Lonza where the Product is Manufactured in compliance      with cGMP and Applicable Laws. Facilities of sub-contractors of Lonza      shall only be deemed Facilities under this Quality Agreement upon prior      written approval of Micromet; |
|--------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | FDA | means      U.S. Food and Drug Administration; |
|--------|-----|-----------------------------------------------|

|   | FEFO | means      First Expired First Out; |
|--------|------|-------------------------------------|

|   | FIFO | means      First In First Out; |
|--------|------|--------------------------------|

|   | ICH | means      International Conference onHarmonization; |
|--------|-----|------------------------------------------------------|

|   | IB(I)MP | means      Intermediate Biological (Investigational) Medicinal Product also known as      Drug Substance; |
|--------|---------|-----------------------------------------------------------------------------------------------------------|

|  | Manufacture /      Manufacturing | means      and includes all operations of the Process used by Lonza for the      production of the Product in accordance with the Product Specification and      cGMP, i.e., receipt of materials, production, packaging, repackaging,      labeling, relabeling, quality control, quality assurance, Release, storage      and distribution of the Product; |
|--|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Product | means      IB(I)MP of MT103 Manufactured under the Development and Supply Agreement      in accordance with the Product Specifications, cGMP and Applicable      Laws; |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Product      Specification | means      the receiving, in-process and finished Product specification for Drug      Substance, set forth in Section A of Schedule 2 of the Development and      Supply Agreement applicable to the Product, as amended in accordance with      the Development and Supply Agreement and this Quality Agreement, and any      amendments to any of the foregoing specifications regarding the Product as      agreed upon by the Parties from time totime; |
|--------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Qualified Person/      QP | means      a person qualified pursuant to Applicable Laws confirming that the Batch      is in accordance with the relevant requirements (as defined in Directive      2001/83/EC for medicinal products for human  use); |
|--------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Quality      Agreement | means      this Quality Agreement which is attached to the Development and Supply      Agreement as Schedule 10; |
|--------|------------------------|------------------------------------------------------------------------------------------------------------------|

|   | Raw      Materials | means      all raw materials, supplies, components and packaging necessary to      Manufacture the Product in accordance with the Product Specification, but      not including the Product |
|--------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Reprocessing | means      the process by which a lot or portion of a lot is purified through repeat      of established and approved Manufacturing steps to produce Product that      meets appropriate standards, specifications and any other relevant control      limit criteria; |
|--------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | SOP(s) | means      the standard operating procedures in effect at Lonza which are applicable      to the Manufacture of the Product and which comply with cGMP and      applicable Laws; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | TSE/BSE | means      Transmissible Spongiform Encephalopathy / Bovine Spongiform      Encephalopathy. |
|--------|---------|---------------------------------------------------------------------------------------------|

----

| 3.1          Organization and Key Personnel                                                                                                                                                                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                 |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                                                            |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                                                                 |   |   |
| ·     Will      maintain a quality unit that is independent of the production unit and has      the responsibility and authority to approve or reject components, Raw      Materials/ [***], bulk packaging materials, Product, SOPs, master Batch      Records, deviation/investigations, and executed production Batch      Records. |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                 |   |   |
| ·     Will      provide and document initial and on-going cGMP and process specific      technical training of employees involved in GMPoperations.                                                                                                                                                                                    |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                 |   |   |
| ·     Will      ensure that the use of consultants is supported by documented verification      that the consultant(s) has(have) the sufficient education, training,      experience, or any combination thereof, to advise on the subject for which      they are retained.                                                           |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                 |   |   |
| ·     Ensure      and allocate adequate number of personnel have appropriate training,      skills, knowledge and experience to perform and supervise the Manufacture      and testing of the Product and the Drug Product in accordance to cGMP and      Applicable Laws.                                                             |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                 |   |   |
| ·     Will      ensure that responsibilities and procedures applicable to the quality unit      are documented in writing and consistently followed.                                                                                                                                                                                   |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                 |   |   |
| ·     Will      conduct internal audits of all relevant activities to ensure compliance      with cGMP and applicable SOPs. Audit findings and corrective actions will      be documented, brought to the attention of Lonza’s Facility management,      and resolved in a timely and effective manner.                          |   | N/A |

----

| 3.2           Buildings,      Facilities, Utilities and Equipment                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                       |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                                                                                  |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Ensure      Facilities, premises, environment, utilities, equipment and computerised      systems are properly designed, validated and maintained in accordance with      cGMP and Applicable Laws.                                                                                                                                                    |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Will      be responsible for ensuring that any Facility owned and operated by a      sub-contractor who performs GMP relevant work operates in compliance with      cGMP and Applicable Laws. Will inform Micromet in advance of its intent to      sub-contract. Will sub-contract only upon written approval from Micromet      for sub-contracting. |   | ·     Approval      of Facilities. |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Provide      a list, upon request, to Micromet of any sub-contractors used to perform      GMP operations, or GMP support operations.                                                                                                                                                                                                                  |   | ·     Review      list. |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Maintain      controlled access to Facilities.                                                                                                                                                                                                                                                                                                         |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Via      change control will notify Micromet as soon as reasonably practicable of      any known changes in ownership of sub-contractors used by Lonza (See Change Control Section      under Section 6.5 for further details).                                                                                                                        |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Ensures      appropriate separation and controls are in place for operation of      multi-product Facilities. An example of a multi site responsibilities      matrix is attached hereto as Annex 2.                                                                                                                                                   |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Review      data provided by Micromet.                                                                                                                                                                                                                                                                                                                 |   | ·     Upon      request, will provide Lonza with Product data/samples required to conduct      cleaning studies. |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Label      and store any Product dedicated equipment to adequately prevent unintended      use for other products.                                                                                                                                                                                                                                     |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Maintain      an environmental water and clean steam monitoring program to ensure      compliance with environmental monitoring regulations and    SOPs.                                                                                                                                                                                               |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Will      qualify, maintain and calibrate equipment and utility services associated      with Manufacturing the Product in accordance with cGMP, Applicable Laws,      and SOPs.                                                                                                                                                                       |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Will      ensure, via validation or verification, that cleaning processes carried      out on Product contact surfaces between batches of different products and      Raw Materials/[***] are adequate to prevent contamination.                                                                                                                       |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                       |   |   |
| ·     Will      maintain complete and accurate cleaning and use logs of equipment used for      the Manufacture of Product                                                                                                                                                                                                                                   |   | N/A |

----

| 3.3           Raw      Materials Controls                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                                                                                                                               |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Source,      test and release Raw Materials and/or primary packaging of appropriate      quality for processing of Product                                                                                                                                                                                                                                                                          |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Ensure      that all animal derived Raw Materials used for Product are appropriately      tested in line with cGMP and Applicable Laws.                                                                                                                                                                                                                                                             |   | ·     As      applicable, provide information to Lonza on any known animal derived Raw      Materials requested for use in the Manufacturing. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Assess      and approve Suppliers of Raw Materials and components in accordance with      the relevant Lonza SOPs.                                                                                                                                                                                                                                                                                  |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Retain      representative samples of critical Raw Materials, as appropriate and in      accordance with the relevant SOP(s) and cGMP for retention      samples;  ·     Store,      under appropriate conditions, a quantity sufficient to perform at least      two (2) full analyses, according to the relevant SOP.                                          |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Establish      and maintain specifications for GMP materials as per SOPs.                                                                                                                                                                                                                                                                                                                           |   | ·     As      applicable, specify any special requirements for specifications of GMP      materials used in the process. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Utilize      either FEFO or FIFO strategy for consumption of GMP    materials.                                                                                                                                                                                                                                                                                                                      |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Use      Product bulk packaging and labelling information specified by      Micromet;  ·     If      not specified by Micromet, utilize Lonza generic bulk packaging and      labelling configurations as per SOP(s).                                                                                                                                            |   | ·     Approve Product bulk      packaging and information on the label |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Will      be responsible for maintenance of specifications of the Raw Materials /      [***].                                                                                                                                                                                                                                                                                                       |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| N/A                                                                                                                                                                                                                                                                                                                                                                                                                                     |   | ·     Will      approve all sources of Raw Materials/ [***] and other materials used in      the process. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Will      be responsible for procurement, storage, sampling, testing, release,      assigning expiration or re-test dating, and maintaining records for each      delivery of Raw Materials/[***].                                                                                                                                                                                                  |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                    |   |   |
| ·     Will      maintain a program to audit (if required) and qualify suppliers      of  critical Raw Materials/ [***] used in the Manufacturing      of   Product to ensure full compliance with cGMP and      Applicable Laws and to verify the status of Raw Materials/[***] of animal      origin with respect to Transmissible Spongiform Encephalopathy (TSE)      issues. |   | N/A |

----

| 4.1          Cell      Banks                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                |
| Lonza Responsibility                                                                                                                                                                                           |   | Micromet Responsibility |
|                                                                                                                                                                                                                |   |   |
| ·     Review      and approve characterisation data and store working stock of      Cell Banks in accordance with the Development and Supply Agreement      and Applicable Laws. |   | ·     Supply      Cell Banks and characterisation data. |
|                                                                                                                                                                                                                |   |   |
| ·     Discuss      any unexpected result with Micromet and agree action(s) to be      taken.                                                                                          |   | ·     If      Cell Banks are tested by any other organisation other than Lonza, any      unexpected results must be reported to Lonza within  [***]. |
|                                                                                                                                                                                                                |   |   |
| ·     Review      data.                                                                                                                                                               |   | ·     Provide      shipping validation for shipping container used to ship Cell      Banks. |
|                                                                                                                                                                                                                |   |   |
| ·     Will      store the [***] (as well as the [***] [***] after generation through      Lonza) [***].                                                                               |   | N/A |
|                                                                                                                                                                                                                |   |   |
| ·     Prepare,      characterize and store [***] per SOPs.                                                                                                                            |   | N/A |

| 4.2          Product      Specification                                                                                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                             |
| Lonza Responsibility                                                                                                                                                                                                                                                                                        |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                             |   |   |
| ·     Jointly      review, approve  and issue the following      Product Specification(s) as required per Development and Supply      Agreement: ·     IB(I)MP ·     Drug      Product.  |   | ·     Jointly      review and approve, via the Micromet approval form, the following      Product Specification(s) as required per Development and Supply      Agreement: ·     IB(I)MP ·     Drug      Product. ·     Complete      review, resolution of any questions and approval of Product Specification      within [***] from date of receipt or within another timeline that has been      mutually agreed by Micromet and Lonza. |
|                                                                                                                                                                                                                                                                                                             |   |   |
| ·     In      accordance with Lonza Quality Standard GROUP-2500, jointly review, approve      and issue the master certification documents (e.g. CofA, CofC...etc), as      required per Micromet.                                                                                 |   | ·     Review      and approve, via the Micromet approval form, the required master      certification documents, as applicable; ·     Complete      review, resolution of any questions and approval of master product      certification documents within [***] from date of receipt or within      another timeline that has been mutually agreed by Micromet and      Lonza. |

| 4.3           Production,      Process Handling and Process Control                                                                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                    |
| Lonza Responsibility                                                                                                                                                                                                                               |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                    |   |   |
| ·     Prepare,      approve and maintain process documents relating to facility, equipment and      test methods.                                                                                                         |   | N/A |
|                                                                                                                                                                                                                                                    |   |   |
| ·     Will      develop, optimize and scale up Manufacturing processes in compliance with      the requirements set forth in the guideline ICH Q8,R1 (Pharmaceutical      Development) and make use of Quality by Design. |   | N/A |

----

| ·     Will      perform quality risk management as Part of development in compliance with      the requirements set forth in chapter II.3 of the guideline ICH Q9      (Pharmaceutical Development) and therefore will: ·     assess      the critical attributes of Raw Materials; ·     identify      critical process parameters and establish manufacturing      controls. |   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Will      compile a development report in a form suitable for incorporation into      regulatory submissions (i.e. IMPD/IND).                                                                                                                                                                                                                                                                                                                  |   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Will      ensure that Product Manufactured is appropriately tested according to      agreed upon sampling and testing plans, Product Specification and approved      procedures.                                                                                                                                                                                                                                                               |   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Jointly      review, approve and issue process descriptions.                                                                                                                                                                                                                                                                                                                                                                                   |   | ·     Complete      review of technical content, resolution of any questions and approval of      process description within [***] from date of receipt or within another      timeline that has been mutually agreed by Micromet and Lonza. Approval to      be captured via the Micromet approval Form; ·     Subsequent      updates to technical content will be captured by change control (see under Section 6.5      below). |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Prepare      master Batch Records for each processing step and make available for      Micromet to review during audit or other mutually defined      frequency.                                                                                                                                                                                                                                                                               |   | ·     Review      master Batch Records for accuracy of technical content for each processing      step and agree.                                                                                                                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Define      specifications and perform in-process controls and testing      program.                                                                                                                                                                                                                                                                                                                                                           |   | ·     Agree      in-process testing strategy.                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     With      Micromet, define process validation plans and timing for Product including      analytical validation and stability studies; ·     Annex 3 contains      additional considerations for Product intended for commercial      use.                                                                                                                                                                  |   | ·     With      Lonza, define process validation plans and timing for Product including      analytical validation and stability studies; ·     Annex 3 contains      additional considerations for Product intended for commercial      use.                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Designate      unique Batch numbers for Raw Materials, process materials and      Product.                                                                                                                                                                                                                                                                                                                                                     |   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Maintain      the Specifications file for Product ·     Notify      Micromet of any changes to the Specifications file; ·     Assurance      of consistency of current Specifications file and IMPD/ IND versions and      notify Micromet.                                                                                                                              |   | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ·     Unless      due to emergency whereby product integrity is at risk, Lonza will not      Reprocess Product without prior notification and written approval of      Micromet.                                                                                                                                                                                                                                                                     |   | ·     If      notification received prior to Reprocessing by Lonza, complete review,      resolution of any questions and approval of Reprocessing requests within      [***]; ·     Following      emergency Reprocessing by Lonza, complete review, resolution of any      questions and approval of Reprocessing deviation/investigation within      [***].                                                                      |

----

| ·     Provide      documented reason and justification for Reprocessingevent.                                                   |   | N/A                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                          |   |                                                                                                                                                      |
| ·     With      Micromet, agree the appropriate testing required prior to the release of      processed or Reprocessed Product. |   | ·     With      Lonza, agree the appropriate testing required prior to the release of      processed or ReprocessedProduct. |

| 4.4           Product      Storage, Labeling, Packaging and Shipment                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                    |
| Lonza Responsibility                                                                                                                                                                                               |   | Micromet Responsibility |
|                                                                                                                                                                                                                    |   |   |
| ·     Will      maintain procedures to ensure Product is stored under appropriate      environmental conditions as defined by Micromet.                                                   |   | ·     Specify      to Lonza all applicable storage requirements for  Product. |
|                                                                                                                                                                                                                    |   |   |
| ·     Store,      label and package (including transport packaging) Product as defined in      the Product Specification.                                                                 |   | N/A |
|                                                                                                                                                                                                                    |   |   |
| ·     Notify      Micromet of proposed shipment date.                                                                                                                                     |   | ·     Agree      shipment date. |
|                                                                                                                                                                                                                    |   |   |
| ·     Ship      Product on behalf of Micromet to locations designated by      Micromet.                                                                                                   |   | ·     Acknowledge      receipt of Product in writing within [***] of receipt. |
|                                                                                                                                                                                                                    |   |   |
| ·     Provide      generic shipping validation data, where available, for Product if      requested by Micromet.                                                                          |   | ·     Provide      Product specific shipping validation OR, where applicable, request in      writing to utilize Lonza generic shipping validation for      Product. |
|                                                                                                                                                                                                                    |   |   |
| ·     If      Product is to be shipped under quarantine ensure written confirmation      received from Micromet to authorise shipment of Product under quarantine      prior to shipment. |   | ·     Provide      Lonza with written confirmation to authorise shipment of Product under      quarantine. |

| 5.1          QC      Laboratory Controls                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                           |
| Lonza Responsibility                                                                                                                                                      |   | Micromet Responsibility |
|                                                                                                                                                                           |   |   |
| ·     Assess      and approve contract testing laboratories for Raw Material, Cell Banks,      Product Release testing and Drug Product testing. |   | N/A |
|                                                                                                                                                                           |   |   |
| ·     Notify      Micromet of contract testing laboratories used for Product Release testing      and Drug Product testing.                      |   | ·     Agree      proposed use of contract testing laboratories. |
|                                                                                                                                                                           |   |   |
| ·     Audit      contract testing laboratories in accordance with GxP guidelines and      confirm audit to Micromet in writing.                  |   | N/A |
|                                                                                                                                                                           |   |   |
| ·     Facilitate audit by Micromet      if requested.                                                                                            |   | ·     May      perform audits of Lonza contract testing laboratories providing Micromet      is authorized to do so by the contract laboratory and accompanied by a      Lonza representative. |
|                                                                                                                                                                           |   |   |
| ·     Review      and approve Micromet strategy and deliverables for establishing analytical      methods for process.                      |   | ·     Define      strategy and deliverables for establishing analytical methods to be used      in support of process, including: o     Methods to be      developed by Lonza; o     Methods to be      transferred to Lonza fromexternal |

----

| ·     Will      submit any proposed major changes to analytical methods related to the      testing of Product and Drug Product to Micromet for review and approval      prior to the implementation of such changes. Change request notification      and approval will be documented according to the applicable      SOP. |   | ·     Will      submit any proposed major changes to analytical methods related to the      Drug Product and Product to Lonza for review and approval prior to the      implementation of such changes. Change request notification and approval      will be documented.                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Will      not implement proposed major changes until written approval is received      from Micromet.                                                                                                                                                                                                                  |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Will      be responsible for performing [***] identification test on each lot of Raw      Materials in accordance with approved analytical methods and      specifications, compendial methods and SOPs.                                                                                                               |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Will      be responsible for performing all in-process testing in accordance with      approved procedures.                                                                                                                                                                                                            |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Will      provide Micromet with a Certificate of Analysis and a Certificate of      Compliance as well as a QP Certification statement individually or as      combined documentation.                                                                                                                                 |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Perform      Product and Drug Product testing against Product and Drug Product      Specification.                                                                                                                                                                                                                     |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Notify      Micromet of confirmed out of Specification results (OOS) regarding Product      Release testing and Drug Product testing.within target of [***], not to      exceed [***], of the OOS being confirmed.                                                                                                     |   | ·     Complete      review, resolution of any questions and approval of investigation reports      within [***] regarding any out of Specification result (OOS) of Product      and Drug Product ·     For      target specifications agree impact on quality and safety of Product and      Drug Product. |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Will      provide Micromet with a written report on the investigation and resolution      of the OOS test result within [***] of confirmation of the result, unless      granted approval by Micromet for a longer period.                                                                                             |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Take      bulk Product retention samples from each Batch with sufficient volume for      at least [***] full biochemical Product Specification analyses for      use in the event of an investigation on Product Released for clinical      trial supply.                                                         |   | ·     Define      number of samples required to complete full biochemical      analysis.                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Store      retains under appropriate conditions for the period defined in      SOPs.                                                                                                                                                                                                                                   |   | N/A                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                                                                                                                                                                                                                                                                                       |   |                                                                                                                                                                                                                                                                                                                                                                        |
| ·     Upon      completion of sample retention period notify Micromet of option to either      destroy or ship retention in accordance with SOPs.                                                                                                                                                                            |   | ·     Within      [***] respond in writing to Lonza and approve destruction of samples or      request receipt ofsamples.                                                                                                                                                                                                                     |

----

| ·     Jointly      agree to analytical method development and/or method transfer strategy for      Product and Drug product testing; ·     Strategy      to include deliverables for all applicable methods to be developed,      validated, transferred and qualified, as applicable. |   | ·     Jointly      agree to analytical method development and/or method transfer strategy for      Product testing; ·     Strategy      to include deliverables for all applicable methods to be developed,      validated, transferred and qualified, as applicable. |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                   |
| ·     Will      be responsible for qualifying and maintaining all laboratory equipment      used for all testing applicable to the Manufacture of    Product.                                                                                                                                                             |   | N/A                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                   |
| ·     Perform      Product stability testing according to Development and Supply      Agreement; ·     Prepare      stability protocols.                                                                                                                                               |   | ·     Jointly      define stability testing requirements and responsibilities; ·     Approve      stability protocols.                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                   |
| ·     Notify      Micromet within target of [***], not to exceed [***], of any confirmed      stability failure of the Product at the intended storage      temperature.                                                                                                                                                  |   | ·     Acknowledge      receipt of Lonza notification, in writing, within[***].                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                   |
| ·     Prepare,      characterise and store Product reference standard perSOPs.                                                                                                                                                                                                                                            |   | ·     Agree      to reference characterisation package.                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                   |
| ·     Provide      reference standard characterisation report to Micromet.                                                                                                                                                                                                                                                |   | ·     Agree      to reference characterisation package.                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                    |   |                                                                                                                                                                                                                                                                                                                                   |
| ·     Store      characterised Product reference standard under appropriate conditions as      per SOPs.                                                                                                                                                                                                                  |   | ·     Supply      characterised Product reference standard with      Certificate of Analysis.                                                                                                                                                                                                  |

| 6.1          Complaints,      Recalls and Adverse Events                                                                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                      |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                      |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                      |   |   |
| ·     Upon      request, support Micromet in their Product complaint or adverse event      investigations for events possibly related to Lonza; ·     Jointly      agree to investigation plan, actions and time lines for response, as      applicable. |   | ·     Receive      and investigate Product complaint and adverse events and request Lonza      support, as applicable; ·     Jointly      agree to investigation plan, actions and time lines for response, as      applicable; ·     Responsible      for all notifications to regulatory agencies, as applicable, related to      product complaints or adverse events. |
|                                                                                                                                                                                                                                                                                                                      |   |   |
| ·     Upon      request, support Micromet in activities related to Product recall where      recall relates to Lonza.                                                                                                                                                                       |   | ·     Responsible      for decision to initiate a Product recall; ·     Responsible      for overall management of Product recall  activities. |

----

| 6.2          Batch      Review and Product Disposition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |   |
| ·     Review      Batch Record for compliance to cGMP, SOPs and the Product      Specification.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |   |
| ·     Will      provide Micromet upon its request, one (1) agreed copy of Product Batch      documentation for each production Batch (as detailed in Annex 4). This will      include Product analysis as defined in the Product Specification, a      summary of Batch related deviations, environmental monitoring summaries,      TSE / BSE statements, Certificate of Compliance, Release certificate.      Proprietary information such as media and feed preparations may be      excluded. Lonza to provide information directly to regulatory      authorities. |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |   |
| ·     Prepare      Certificate of Analysis for Product as specified by      Micromet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |   |   |
| ·     Responsible      for Certification of Product to Micromet "for use in further      manufacturing" of clinical trial materials by a Qualified      Person.                                                                                                                                                                                                                                                                                                                                                                                                         |   | ·     Responsible      for Certification of Product for use in clinical trials and/or markets      supplied (unless otherwise specified contractually with      Lonza). |

| 6.3          Records      Retention                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                             |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                             |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                             |   |   |
| ·     Retain      records associated with Manufacture of Product and testing of Product and      Drug Product, including records associated with the inspection and Release      of Raw Materials and primary packaging components, for minimum of [***]      from date of Manufacture of Product. |   | N/A |
|                                                                                                                                                                                                                                                                                                                             |   |   |
| ·     Notify      Micromet of intent to destroy records with option to send records (Lonza      proprietary information will be omitted) to Micromet OR ·     Agree      terms with Micromet for future storage.                                           |   | ·     Approve      destruction or request receipt ofrecords. |

----

| 6.4          Deviations      / Investigation Reports                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   |   |
| ·     Deviation      handling, investigation and clarification of any cell culture      contamination, any deviation potentially bearing a risk of a defective      batch run, potential loss of a batch due to technical defects or operator      errors ·     General      deviation handling in accordance with Lonza procedures, initiate      deviations/investigations, evaluate and define follow up actions and final      approval of deviations / investigation reports. |   | N/A |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   |   |
| ·     Notify      Micromet of all significant deviations within target of [***], not to      exceed [***] of the event; ·     A      significant deviation is as defined as per Lonza’s relevant      SOPs; ·     Upon      request, provide Micromet with copy of draft report of significant      deviation for review and comments.                                                                                                    |   | ·     Acknowledge      receipt of significant deviation draft report, in writing, within      [***]; ·     Provide      any questions/comments to draft Lonza report within  [***]. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   |   |
| ·     Notify      Micromet of failed Batches within target of [***], not to exceed [***] of      failure being identified.                                                                                                                                                                                                                                                                                                                                                                                            |   | ·     Acknowledge      receipt of failure investigation draft report, in writing, within      [***]; ·     Provide      any questions/comments to draft Lonza report within  [***]. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |   |   |
| ·     Within      target of [***], not to exceed [***], notify Micromet of any events noted      which may impact Batches previously shipped or Released; ·     Upon      request, provide Micromet with copy of draft report of noted deviation for      review and comments.                                                                                                                                                                                                     |   | ·     Acknowledge      receipt of notification, in writing, within [***]; ·     Provide      any questions/comments to draft Lonza report within  [***]. |

| 6.5           Change      Control Procedures                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                    |
| Lonza Responsibility                                                                                                                                                                                                                                                    |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                                    |   |   |
| ·     For      a Product specific change proposed by Micromet: process change through      change control and notify Micromet of change approval.  If      change rejected discuss reasons for rejection with    Micromet.      |   | ·     Propose      Micromet changes and provide rationale in writing. |
|                                                                                                                                                                                                                                                                    |   |   |
| ·     Will      provide Micromet with all information required to evaluate the proposed      changes and, if necessary, obtain amended clinical trial applications, as      applicable.                                                   |   | N/A |
|                                                                                                                                                                                                                                                                    |   |   |
| ·     Lonza      will not implement major changes (i.e., changes which are relevant for      regulatory approval) until written change request approval is received      from Micromet.                                                   |   | ·     Approval of major change or      rejection. |
|                                                                                                                                                                                                                                                                    |   |   |
| ·     For      major changes proposed by Lonza, Lonza will provide Micromet with all      information required to evaluate such proposed changes and, if necessary,      to obtain amended clinical trial applications, as    applicable. |   | N/A |

----

| ·     Notify      Micromet, through change control, of any proposed changes to Product or      process specific attributes prior to implementation.      |   | ·     Complete      review, resolution of any questions and approval within [***] of receipt      of change controls. |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                   |   |                                                                                                                                                |
| ·     Inform      Micromet of changes to key personnel.                                                                                                  |   | N/A                                                                                                                                                 |
|                                                                                                                                                                                   |   |                                                                                                                                                |
| ·     Notify      Micromet, through change control, of relevant changes to major equipment,      premises and utilities used for Manufacture of Product. |   | ·     Acknowledge      receipt of notification, in writing, within [***].                                             |
|                                                                                                                                                                                   |   |                                                                                                                                                |
| ·     With      Micromet, define strategy for notifying change to regulatory agency      as appropriate.                                            |   | ·     With      Lonza, define strategy for notifying changes      to regulatory agency asappropriate.                 |

| [***]      [***]                                                                                                                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                   |
| Lonza Responsibility                                                                                                                                                                                                                                   |   | Micromet Responsibility |
|                                                                                                                                                                                                                                                   |   |   |
| ·     Provide      Micromet with daily verbal debriefs of inspection scope during      inspections.                                                                                                                      |   | ·     Provide      required technical, quality and regulatory representatives on site for      pre-approval inspections, as agreed with Lonza; ·     Provide      up to [***] ([***] to be agreed by Lonza) to be present directly in      meetings with agency inspectors. |
|                                                                                                                                                                                                                                                   |   |   |
| ·     Provide      copies of inspection reports and notify Micromet of proposed responses and      corrective action plans regarding the Product, process or systems relating      to Product.                           |   | ·     Agree      on proposed inspection responses to observations relevant to      Product. |
|                                                                                                                                                                                                                                                   |   |   |
| ·     Inform      Micromet of any regulatory agency inspections at    Facilities.                                                                                                                                        |   | ·     For      regulatory agency inspections regarding Product provide assistance to      Lonza. |
|                                                                                                                                                                                                                                                   |   |   |
| ·     Notify      Micromet of inspection observations (including deficiency letters)      regarding the Product, process or systems relating to the      Product.                                                        |   | ·     Agree      on proposed inspection responses to observations relevant to      Product. |
|                                                                                                                                                                                                                                                   |   |   |
| ·     Will      permit an employee and/ or consultant and/or successor of Micromet or      Micromet's sublicensee(s) to be present as silentobserver.                                                                    |   | N/A |
|                                                                                                                                                                                                                                                   |   |   |
| ·     Will      appropriately and promptly correct verifiable complaints of regulatory      agencies; ·     Will      implement appropriate actions as agreed upon by the    Parties. |   | ·     Agree      on proposed actions to complaints by regulatory  agencies. |

----

| 7.2           Regulatory      Authorizations / Submissions                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                    |
| Lonza Responsibility                                                                                                                                                                                                    |   | Micromet Responsibility |
|                                                                                                                                                                                                                    |   |   |
| ·     Maintain      all licenses and authorizations as are required by Applicable Laws to      operate a cGMP pharmaceutical bulk manufacturing, packaging, and/or      testing facility. |   | N/A |
|                                                                                                                                                                                                                    |   |   |

| ·     Will      provide copies of all documentation necessary for Micromet to respond to      inquiries by regulatory agencies relating to Product.                                                                                                            |   | ·     Will      provide copies of all documentation necessary for Lonza to respond to      inquiries by regulatory agencies relating to Product.                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                         |   |                                                                                                                                                                                                                                                         |
| ·     Provide      data pack to Micromet covering activities performed by Lonza (Lonza      proprietary information will be omitted) for review and      comment; ·     Provide      Micromet with final copy of data pack. |   | ·     Review      and comment on draft data pack.                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                         |   |                                                                                                                                                                                                                                                         |
| ·     For      US submissions, provide letter authorising cross referral to [***] if      requested by Micromet.                                                                                                                                               |   | ·     Provide      Lonza with copy of relevant sections of regulatory application as      submitted to regulatory agency.                                                                                                      |
|                                                                                                                                                                                                                                                                                         |   |                                                                                                                                                                                                                                                         |
| ·     Review      and comment on relevant sections of Micromet’s regulatory      application.                                                                                                                                                            |   | ·     Prepare      and provide Lonza with copy of relevant sections of regulatory application      for review and comment prior to submission to regulatory      agency.                                                       |
|                                                                                                                                                                                                                                                                                         |   |                                                                                                                                                                                                                                                         |
| N/A                                                                                                                                                                                                                                                                                          |   | ·     Provide      Lonza with copy of relevant sections of regulatory application as      submitted to regulatory agency.                                                                                                      |
|                                                                                                                                                                                                                                                                                         |   |                                                                                                                                                                                                                                                         |
| ·     Attend      teleconferences and meetings between Micromet and regulatory agencies      arranged to specifically discuss topics relating to Lonza’s      responsibilities, if requested by Micromet.                                           |   | ·     Arrange      for Lonza personnel to have option to attend teleconferences and meetings      between Micromet and regulatory agencies to specifically discuss      topics relating to Lonza’sresponsibilities. |

| 8.1          Audit      Allowance                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lonza Responsibility                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   | Micromet Responsibility |
| ·     [***] standard      cGMP compliance audit permitted per [***] and per [***], not to exceed      [***] and [***]; ·     Will      permit Micromet's Person-in-Plant (PiP) observe Works and Services in      accordance with the Development and Supply Agreement; ·     Micromet      may request ‘for cause’ audits and investigations to address Product      quality issues after prior notification. |   | ·     Provide      reasonable notice of intention to audit; ·     Hold      an exit meeting to discuss observations; ·     Provide      an audit report within [***] of completion of audit. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |   |   |
| ·     Permit      Micromet representatives or third parties commissioned by Micromet for a      permitted audit to have access to GMP warehousing, manufacturing areas,      laboratories and Manufacturing documents including all standard operating      procedures (Lonza proprietary information will be omitted) for audit      purposes; ·     Micromet      representatives to be escorted at all times by Lonza      personnel.                                |   | N/A |

----

| ·     Per      lot, allow a [***] on site review for up to [***] to review completed      process Batch Records, if requested by Micromet.                                                           |   | ·     Per      lot, provide reasonable notice of intention to review executed Batch      Records. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                               |   |                                                                                                                            |
| ·     Provide      a written response to all audit findings that require corrective action      within [***] of receipt of the audit report.  Response to      include expected timelines. |   | N/A                                                                                                                             |
|                                                                                                                                                                                                                               |   |                                                                                                                            |
| ·     Will      appropriately and promptly correct any defects found by audits and      inspections and take any necessary action.                                                                   |   | N/A                                                                                                                             |
|                                                                                                                                                                                                                               |   |                                                                                                                            |
| ·     The      QP responsible for final Release or [***] is entitled to attend all      production campaigns of Product at the Facility as detailed in the      Development and Supply Agreement.    |   |                                                                                                                            |

| 8.2          Periodic      Review of Quality Agreement                                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                              |
| Lonza Responsibility                                                                                                                              |   | Micromet Responsibility |
|                                                                                                                                              |   |   |
| ·     Jointly      review Quality Agreement and revise, as necessary, at least every      [***].                    |   | ·     Jointly      review Quality Agreement and revise, as necessary, at least every      [***]. |
|                                                                                                                                              |   |   |
| ·     Written      approval from both Parties for any amendments to the Quality      Agreement.                     |   | ·     Written approval from both      Parties for any amendments to the Quality Agreement. |
|                                                                                                                                              |   |   |
| ·     Will      provide revision control of the Quality Agreement and issue a revised      document as appropriate. |   | N/A |

----

| 9. | Term |
|----|------|

| 10. | Miscellaneous |
|-----|---------------|

| 10.1 | Sections      1 (Definitions and Interpretation), 5 (Inspections; Person in Plant), 10      (Confidentiality), 15 (Force Majeure), 16 (Governing Law, Jurisdiction and      Enforceability), 17 (Illegality) and 20.1 (Affiliates; Assignment) of the      Development and Supply Agreement shall also apply to this Quality      Agreement. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | In      case of conflicts between this Quality Agreement and the Development and      Supply Agreement, the provisions of the Development and Supply Agreement      shall govern and control. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | No      variation of or addition to this Quality Agreement or any part thereof      shall be effective unless in writing and signed on behalf of both      Parties.  Notwithstanding the above the Parties hereby confirm      that amendments to the Product Specification and the Drug Product      Specifications shall be effective if reduced to writing and signed by the      quality and/or regulatory representative of both Parties, which quality      and/or regulatory representative shall be nominated from time to time by      each Party. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Micromet      AG                                                        |                                        | Lonza      Sales AG                                      |
|-------------------------------------------------------------------------|---------------------------------------------|----------------------------------------------------------|
|                                                                    |                                        |                                                     |
| Signature:                                                              |    /s/ Jens      Hennecke    |                                                     | Signature: |   /s/ Una  Hultry |
| Printed      Name:  Jens Hennecke                             |                                        | Printed      Name:    Una Hultry          |
| Title:      SVP      Business Development |                                        | Title:      Authorized Signatory                         |
|                                                                    |                                        |                                                     |
| Signature:                                                              |    /s/ Patrick      Baeuerle |                                                     | Signature: |    /s/ Gerry      Kennedy |
| Printed      Name:  Patrick Baeuerle                          |                                        | Printed      Name:     Gerry Kennedy |
| Title:  SVP,      Chief Scientific Officer                    |                                        | Title:  Authorized      Signatory              |

----

| Micromet                                   |                                                   | Lonza                                   |
|--------------------------------------------|--------------------------------------------------------|-----------------------------------------|
| Head      of Quality: Klaus Buchweitz      |                                                   | Head      of Quality (LBP): Sue Crowe   |
|                                       |                                                   |                                    |
| Signature:                                 |      /s/ Klaus      Buchweitz |                                    | Signature: |     /s/ Sue      Crowe |
|                                       |                                                   |                                    |   |   |
| Head      of Manufacturing: Thomas Urbig   |                                                   | Head      of Operations: Gordon Bates   |
|                                       |                                                   |                                    |
| Signature:                                 |     /s/ Thomas      Urbig          |                                    | Signature: |     /s/ Gordon      Bates |
|                                       |                                                   |                                    |   |   |
| Head      of Quality Control: Andreas Wolf |                                                   | Head      of Quality Control: Kym Baker |
|                                       |                                                   |                                    |
| Signature:                                 |     /s/ Andreas      Wolf          |                                    | Signature: |     /s/ Kym      Baker |

----

----

| Micromet                            |   | Lonza                               |
|-------------------------------------|--------|-------------------------------------|
| Head      of Site: N/A              |   | Head      of Site: [***]            |
|                                |   |                                |
|                                |   | Tel:                                | [***] |
|                                |   | Fax:                                | [***] |
|                                |   | Email:                              | [***] |
| Head      of Quality: [***]         |   | Head      of Quality: [***]         |
|                                |   |                                |
| Tel:                                | [***]  |                                | Tel: | [***] |
| Fax:                                | [***]  |                                | Fax: | [***] |
| Email:                              | [***]  |                                | Email: | [***] |
| Head      of Manufacturing: [***]   |   | Head      of Operations: [***]      |
|                                |   |                                |
| Tel:                                | [***]  |                                | Tel: | [***] |
| Fax:                                | [***]  |                                | Fax: | [***] |
| Email:                              | [***]  |                                | Email: | [***] |
| Head      of Quality Control: [***] |   | Head      of Quality Control: [***] |
|                                |   |                                |   |
| Tel:                                | [***]  |                                | Tel: | [***] |
| Fax:                                | [***]  |                                | Fax: | [***] |
| Email:                              | [***]  |                                | Email: | [***] |

----

----

| Site Specific Responsibility                                         |         | Responsible Lonza Facility |         | Comments                                                                                                   |
|--------------------------------------------------------------------------------|--------------|--------------------------------------|--------------|------------------------------------------------------------------------------------------------------------|
|                                                                           |         |                                 |         |                                                                                                       |
| GMP      Manufacture, process development, cell bank creation and      storage |         | [***]                                |         | Primary      Manufacturing Facility ([***])                                                                |
|                                                                           |         |                                 |         |                                                                                                       |
| Serve      as back-up storage facility for Micromet's cell banks               |         | [***]                                |         | Storage      facility for Micromet cell banks                                                              |
|                                                                           |         |                                 |         |                                                                                                       |
| Pre-Licence      Stability Studies and Bioassays                               |    | [***]                                |    | Primary      Facility for stability studies and bioassays for Product produced at the      slough Facility |

----

----

| [***]                |
|----------------------|
| Lonza Responsibility |   |   | Micromet Responsibility |
| ·               | For      Lonza supplied materials, finalize critical supplier and critical Raw      Material qualifications for the Product |   | · | For      Micromet supplied materials, finalize critical supplier and critical Raw      Material qualifications for the Product. |
|                 |   |   |   |   |
| [***]                |
| Lonza Responsibility |   |   | Micromet Responsibility |
| ·               | Jointly      with Micromet, define strategy and responsibilities for process validation      activities including (but not limited to): |   | · | Jointly      with Lonza, define strategy and responsibilities for process validation      activities including (but not limited to): |
|                 |   |   |   |   |

| o      | Process      validation master plan,                | o      | Process      validation master plan, protocols and reports; |
|--------|-----------------------------------------------------|--------|-------------------------------------------------------------|
|   | protocols      and reports (issued before           | o      | Product  specific      assay validations;         |
|   | phase      III material is manufactured);           | o      | Cleaning      validation of the  Product          |
| o      | Product  specific      assay validations; | o      | Hold      times for buffers/medias used in process;         |
| o      | Cleaning      validation of the  Product  | o      | Product      stability;                                     |
| o      | Hold      times for buffers/medias used in process; | o      | Product      yield specifications.                          |
| o      | Intermediate  Product      stability;     |   |                                                        |
| o      | Product      yield specifications.                  |   |                                                        |

----

----

----

----

----

----

----

----

----

| (1) | LONZA SALES AG, of      Muenchensteinerstrasse 38, CH-4004, Basel, Switzerland (hereinafter      referred to as “the      Licensor”). |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | MICROMET AG, of      Staffelseestrasse 2, D-81477 Munich, Germany (hereinafter referred to as      “the Licensee”). |
|-----|---------------------------------------------------------------------------------------------------------------------------------|

| (A) | Pursuant      to the Development Agreement (as defined below), the Licensor has      performed certain development and manufacturing services on behalf of the      Licensee relating to the Product, and accordingly the Licensor possesses      confidential and proprietary information and data concerning the      manufacture of the Product. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (B) | The      Licensor and the Licensee have previously entered into the Development      Agreement dated November 23, 2009 relating to, inter alia, the Licensee’s      use of certain Intellectual Property of the Licensor in the research,      development and manufacture of theProduct. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C) | The      Licensor has agreed to transfer the Product specific documentation and      appropriate information and grant the licenses needed for the Licensee and      its Permitted Sublicensees (as defined below) to replicate the Process in      the event Licensee or its successor exercises its option for a technology      transfer and license as set forth in Clause 14 of the Development      Agreement.  Upon exercise of the option, the Licensor shall make      available to the Licensee such confidential and proprietary information      and shall grant to the Licensee a non exclusive licence to use the      Licensed Know-How, the Licensed Patents and other Intellectual Property      for the further development and manufacture of the  Product. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1 | INTERPRETATION |
|---|----------------|

|   | 1.1 | The      definitions and rules of interpretation in this Clause apply in this TTL      Agreement. |
|--------|-----|---------------------------------------------------------------------------------------------------|

|   | 1.1.1 | Affiliate means any      company, corporation, limited liability company, partnership or other      entity which directly or indirectly Controls, is Controlled by or is under      common control, directly or indirectly, with the relevant Party to this      Agreement.  Control for purposes of      this Clause 1.1.1 shall mean the ownership of more than fifty percent      (50%) of the issued share capital of the Party in question or the legal      power to direct or cause the direction of the general management and      policies of the Party in question. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.2 | Approved Purpose means,      in relation to the Product only (and no other product), the further      development of the Process and the manufacture of the Product using the      Process and the Intellectual Property, the Licensed Know-How and the      Licensed Patents by the Licensee and/or its Permitted Sublicensees, and      the sale and use of the Product for anypurpose. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.3 | Control or Controlled means with      respect to any (i) item of Information, including, without limitation,      know-how, or (ii) Intellectual Property, the possession (whether by      ownership or license, other than pursuant to this TTL Agreement) by a      Party of the ability to grant to the other Party access or a license as      provided herein under such item or right without violating the terms of      any agreement or other arrangements with any Third  Party. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.4 | Development Agreement      means that certain agreement dated November 23, 2009 between the      Licensor and the Licensee relating to the development of the Process and      the manufacture of the Product. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.1.5 | Disclose includes      discussion (or any communication) or disclosure, by whatever means, and      Disclosed, Discloses,      Disclosing and Disclosure are to be      construed accordingly, and in relation to an obligation to Disclose means      the most appropriate form ofDisclosure. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.6 | Effective Date of this TTL      Agreement means the date on which the Licensee exercises the option      for a technology transfer and license in accordance with Clause 14 of the      Development Agreement. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.7 | Improvement means any      addition, alteration, change, development, enhancement, improvement or      modification to and non-severable from the Licensed Know-How and/or      Licensed Patents, and includes all Information in respect of the same, to      the extent severable from the Product and the Licensee’s patents and      know-how. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.8 | Information means any      information, including technical information and know-how, obtained from      development, experimentation, observation and operation by the Disclosing      Party or on its behalf or to which it is or becomes entitled and all      analyses, assessments, data, designs, details, diagrams, drawings,      opinions, specifications and statements in the Control and possession or      within the knowledge of the DisclosingParty. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.9 | Intellectual Property      means all intellectual property rights, including (without      limitation) patents, patent applications, divisions, continuations,      continuation-in-part applications, divisionals, substitutions,      confirmations, supplementary protection certificates, reissues, utility      models, trademarks, database rights and copyrights and all inventions,      know-how, trade secrets, techniques and confidential information and other      proprietary knowledge and information which may subsist anywhere in the      world, in each case for their full term, and together with any renewals or      extensions. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 1.1.10 | Licensed Know-How means      all technical and other Information or data owned or Controlled by the      Licensor and used in the development and/or manufacture of the      Product.  Licensed Know-How shall include but not be limited to      scientific, technical, and commercial information relating to the Process,      such as specifications, know-how, technologies, manufacturing processes,      research, inventions and the Licensor’s commercial activities, and further      including any know-how comprised in the New General Application      Intellectual Property, as defined in the Development Agreement as well as      know-how comprised in the Improvements.  In the event the      Licensee exercises its option under Clause 14 of the Development Agreement      also for a technology transfer and license of the [***], Licensed Know-How      shall also include the [***].  Without limiting the foregoing,      the Lonza Know How as of the effective date of the Development Agreement      is identified in Schedule A and      Schedule      C hereto. |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.1.11 | Licensed      Patents means patents and patent applications, divisions,      continuations, continuation-in-part applications, divisionals, extensions,      substitutions, renewals, confirmations, supplementary protection      certificates and reissues, throughout the world owned or Controlled by the      Licensor and used in the development and/or manufacture of the      Product.  Licensed Patents shall also include, but not be      limited to patents and patent applications that cover the New General      Applications Intellectual Property, as defined in the Development      Agreement, as well as patents and patent applications comprised in the      Improvements.  In the event the Licensee exercises its option      under Clause 14 of the Development Agreement also for a technology      transfer and license of the [***], Licensed Patents shall also include the      [***].  Short particulars of the Licensed Patents as of the      effective date of the Development Agreement are set out in Schedule B      hereto. |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.1.12 | Lonza means Lonza Sales      AG and its Affiliates Lonza Biologics plc of Slough, England, Lonza      Biologics Inc of Portsmouth, NH, USA, and Lonza Biologics Porriño S.L. of      Pontevedra-Galicia, Spain. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.13 | Micromet means Micromet      AG and its existing Affiliates which are engaged in the research and      development of BiTE®      antibodies, and their successors in title and lawful    assigns; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.14 | Net Selling Price means      all monies received by or on behalf of the Licensee or its sublicensee      hereunder in respect of the sale of Product in the Territory to a Third      Party in a bona fide arm's length transaction, less the following items to      the extent that they are paid or allowed and included in the invoice      price, whether or not invoiced separately, and determined in accordance      with consistently applied and recognized accounting    standards: |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | normal      discounts actually granted, including without limitation, quantity, trade,      cash and other discounts, rebates and charge-backs, including government      rebates, governmental price reductions and  charges; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | amounts      refunded or credits allowed for Product or other goods returned or not      accepted by customers; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------|

|   | (c) | packaging,      transportation and prepaid insurance charges on shipments or deliveries to      customers; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------|

|   | (d) | taxes,      tariffs, customs duties, surcharges and other governmental charges      actually incurred and paid by Licensee or its sublicensee hereunder in      connection with the sale, exportation, importation or delivery of Product      or other goods to customers. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.1.15 | Party / Parties means Licensor      or Licensee, or Licensor and Licensee, as the context    permits; |
|--------|--------|-------------------------------------------------------------------------------------------------------|

----

|   | 1.1.16 | Permitted Sub-licensee      means a Third Party collaboration partner of the Licensee or a Third Party      who manufactures the Product on behalf of the Licensee or the Third Party      collaboration partner of the Licensee subject to a sublicense in      accordance with Clause 2.3 below; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.17 | Process means the      process (including but not limited to the fermentation process and the      downstream process) for the production of Product which is owned or      Controlled by Licensor and was further developed and/or improved and used      for the manufacture of Product by the Licensor under the Development      Agreement. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.18 | Product means Licensee's      single-chain bispecific anti-CD19 antibody (CD19 BiTE®)      also known as Blinatumomab or MT103, and any [***], including      [***]. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.1.19 | [***] means Licensor’s      chemically defined, [***] consisting of the [***] used either in      combination or individually, as it is used in the development and/or      manufacture of the Product and owned or Controlled by      Licensor. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | [***] means [***], as      more fully set out in Schedule      C; |
|--------|-----|-------------------------------------------------------------------|

|   | (b) | [***] means [***], as      more fully set out in Schedule      C; |
|--------|-----|-------------------------------------------------------------------|

|   | (c) | [***] means the [***]      set out in Schedule      C; |
|--------|-----|--------------------------------------------------------|

|   | (d) | [***] means any      Information specifically relating to the [***].  The [***] as of      the effective date of the Development Agreement is identified in more      detail in Schedule C      hereto; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | [***] means any patents      and applications covering the [***].  The [***] as of the      effective date of the Development Agreement are identified in more detail      in Schedule      C hereto; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (f) | [***] means the [***],      as more fully set out in Schedule      C. |
|--------|-----|-----------------------------------------------------------------------|

|   | 1.1.20 | Territory means      worldwide. |
|--------|--------|---------------------------------|

|   | 1.1.21 | Third Party means any      party other than the Licensor and theLicensee. |
|--------|--------|---------------------------------------------------------------------------|

|   | 1.1.22 | TTL Agreement means this      Technology Transfer and LicenseAgreement. |
|--------|--------|-------------------------------------------------------------------------|

|   | 1.1.23 | Valid Claim means an      issued claim of an issued patent that has not (i) expired or been      cancelled, (ii) been declared invalid by a decision of a court or other      appropriate body of competent jurisdiction, from which no appeal is or can      be taken, (iii) been admitted to be invalid or unenforceable through      reissue, disclaimer or otherwise, or (iv) been abandoned or      disclaimed. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.2 | Any      reference to a Clause is to a Clause of this TTL Agreement, unless it      expressly refers to the DevelopmentAgreement. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------|

|   | 1.3 | Clause      headings do not affect the interpretation of this TTL      Agreement. |
|--------|-----|-----------------------------------------------------------------------------------|

|   | 1.4 | Words      in the singular include the plural and in the plural include the      singular. |
|--------|-----|--------------------------------------------------------------------------------------------|

|   | 1.5 | A      reference to one gender includes a reference to the other      gender. |
|--------|-----|-------------------------------------------------------------------------------|

|   | 1.6 | A      person includes a corporate or unincorporated  body. |
|--------|-----|-------------------------------------------------------------|

|   | 1.7 | A      reference to a particular law is a reference to it as it is in force for      the time being taking account of any amendment, extension, application or      re-enactment and includes any subordinate legislation for the time being      in force made under it. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.8 | Writing      or written includes faxes but note-mail. |
|--------|-----|-------------------------------------------------------|

| 2 | GRANT |
|---|-------|

|   | 2.1 | All      Intellectual Property in and to the Licensed Know-How and the Licensed      Patents and the [***] are and shall remain the exclusive property of the      Licensor.  Neither this TTL Agreement nor any Disclosure of the      Intellectual Property, the Licensed Know-How, the Licensed Patents, and      the [***] shall be deemed by implication or otherwise to vest in the      Licensee any present or future rights in any Intellectual Property, the      Licensed Know-How, the Licensed Patents, and the [***] and no licence is      granted except as explicitly stated in this TTL  Agreement. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.2 | The      Licensor hereby grants to the Licensee, and the Licensee accepts, in      relation only to the Product, a non exclusive licence to use the      Intellectual Property, the Licensed Know-How, the Licensed Patents and/or      the [***] to develop, have developed, to manufacture, have manufactured,      to supply, have supplied, to import, have imported, to use, have used, and      to sell and have sold, the Product in the Territory for the Approved      Purpose only. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.3 | The      Licensee shall have the right to authorize and grant sub-licences through      multiple tiers under this TTL Agreement to specific [***] and any other      Third Party registered and operating within the permitted territories (but      not to [***], their Affiliates or any other Third Party registered and      operating outside the permitted territories) listed in Schedule D (any      [***] or Third Party other than those named, or outside those territories      listed, are to be assessed and consented to by Licensor on a case by case      basis, provided      that such consent by the Licensor shall not be unreasonably      withheld or delayed) with respect to the rights and licences granted under      this TTL Agreement, and further provided      that: |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 2.3.1 | the      Licensee shall at all times indemnify and keep indemnified the Licensor      against all or any cost, claims, damages or expenses incurred by the      Licensor or for which the Licensor may become liable as a result of the      default or negligence of any sub-licensee, (including sub-sub-licensees,      and as further sub-licensed as the case may be), relating to this TTL      Agreement; and/or |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.3.2 | each      sub-license, (including sub-sub-licensees, and as further sub-licensed as      the case may be), shall be expressly subject and subordinate to the terms      of this TTL Agreement, and it shall be the Licensee's responsibility to      ensure the strict adherence by any sublicensee hereunder to the terms and      conditions of this TTL Agreement. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4 | With      regard to the [***] and provided      that the Licensee exercises its option regarding the [***] under      Clause 14 of the Development Agreement, the following provisions shall      apply: |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4.1 | The      Licensor shall offer to Licensee [***].  Such new version shall      be made available at the price set forth in Clause 7.2 below, with the      only additional compensation being for additional Works and Services which      may be required to implement such improvement or new version for the      manufacture of the Product. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 2.4.2 | The      Licensor shall provide the Licensee with details of a Third Party      supplier, from whom the Licensee and/or the Permitted Sub-licensee will be      able to purchase [***] to enable the Licensee and/or the Permitted      Sub-licensee, to make and use the [***], and the Licensor shall also      provide the Licensee or at Licensee's direction the Permitted Sublicensee      with the [***] to the extent required by the Licensee and/or the Permitted      Sub-licensee to use the [***], and to make and use the [***] for the      Approved Purpose. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4.3 | For      the avoidance of doubt, the formulation of the [***] and/or the [***] will      not be Disclosed to the Licensee, and the Licensee hereby confirms that it      shall not perform any analysis, test, experiment, modification or      reverse-engineering on the [***].  With regard to any regulatory      filings necessary to support the Product, the Licensor shall file such      formulations directly with the appropriate regulatory      authority. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4.4 | Upon      the request of Licensee, Licensor shall provide to the Licensee or      directly to the appropriate regulatory authority (as the case may be),      such documents and reasonable assistance regarding the [***] as may be      required to be submitted by Licensee in filings with any applicable      regulatory authorities for theProduct. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4.5 | The      Licensor will provide to certain designated safety experts of the Licensee      or at the Licensee's direction its Permitted Sublicensee with [***] in      order to enable the Licensee or the Permitted Sublicensee to evaluate the      safety of the [***]. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4.6 | The      Licensor shall use reasonable commercial endeavours to ensure continuity      of supply of the [***] and [***], through the establishment of a second      supplier where possible, the establishment of a second source from the      same supplier (e.g. second production site) or the establishment of supply      through an emergency plan/securitystock. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.4.7 | The      Licensee acknowledges that, subject only to [***]; certain Licensor      proprietary information (including the formulation for any elements of      [***]) may be a Licensor trade secret and will only be supplied [***] and      not to [***]. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 2.5 | No      right or licence is granted by the Licensor to the Licensee by this TTL      Agreement, except as expressly set out in this Clause  2. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2.6 | The      Licensor shall execute all documents, give all declarations regarding the      licenses granted under this Clause 2 and reasonably cooperate with the      Licensee to the extent such documents, declarations and/or cooperation are      required for the recordal or registration of the licenses granted      hereunder at the various patent offices for the benefit of the Licensee      and at the Licensee’s cost. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3 | TECHNOLOGY      TRANSFER; PROVISION OF TECHNICALASSISTANCE |
|---|------------------------------------------------------------|

|   | 3.1 | The      Licensor shall transfer and make available to the Licensee, or at the      Licensee's direction to a Permitted Sub-licensee within [***] after the      Effective Date of this TTL Agreement (subject only to Clause 3.2) and from      time to time regarding the [***] a data package that shall include all of      the Information, Licensed Know-How, the Licensed Patents and, upon      exercise of the option regarding the [***] also the [***], in order to      enable the Licensee and/or the Permitted Sub-licensee, to develop,      manufacture, sell and use the Process and the Product.  The      Licensee and the Permitted Sub-licensee shall not use any of the know-how      furnished by the Licensor under this Clause 3 for any purpose whatsoever,      except for the Approved Purpose, or as otherwise specifically authorized      in writing by the Licensor.  In the event that the Licensee      reasonably believes that the Licensed Know-How, to the extent applicable,      included in the data package furnished by the Licensor under this Clause 3      is incomplete, the Licensee shall provide written notice thereof to the      Licensor, and the Licensor shall undertake reasonable efforts to furnish      the missing materials or amended copies of the missing know how and to      answer all reasonable questions received from the Licensee regarding the      Licensed Know How as soon as reasonably possible after receipt of the      Licensee's written notice. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 3.2 | Upon      completion of the technology transfer under Clause 3.1, at the latest      [***] after the Effective Date of this TTL Agreement, the Parties shall      meet to discuss the status of the technology transfer, any missing      know-how and information and the assistance to be provided by the Licensor      in order to allow the Licensee or its Permitted Sub-licensee to      manufacture the Product using the Process.  The Licensee may      invite representatives of its Permitted Sub-licensees to participate in      such meeting. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.3 | After      the Effective Date of this TTL Agreement and until [***] after the meeting      as set forth in Clause 3.2 above took place, the Licensor shall transfer      to the Licensee, or at the Licensee's discretion to its Permitted      Sub-licensee the [***].  Clause 3.1 above shall apply      respectively for the transfer of such[***]. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.4 | During      the term of this TTL Agreement, the Licensor shall reasonably make      available to the Licensee as outlined in the following sentence, the      services of fully qualified and experienced members of its staff to advise      the Licensee on the use of the Information, the Licensed Know-How, the      Licensed Patents and the [***] for the Approved Purpose.  Upon      prior written notice of the Licensee of at least [***] FTEs of the      Licensor will be available for technical assistance for the first [***]      after the Effective Date of this TTL Agreement.  Thereafter,      Licensor will be available for at least [***] during any [***]      period. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.4.1 | the      Licensee reimburses the preapproved reasonable travel, hotel and living      expenses of such persons for the period from departure to      return; |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.4.2 | the      Licensee pays to the Licensor a fee for the services of such person in      relation to time spent with the Licensee and in travelling to and from the      Licensee at the Licensor’s then commercial daily      rate.  Licensor's commercial daily rate on the effective date of      the Development Agreement is [***] subject to annual UK's PPI      adjustments; |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 3.4.3 | the      Licensor's representative shall act merely in an advisory capacity and      neither the Licensor nor such person shall be liable in any manner for any      loss (including, but not limited to, consequential loss, pecuniary loss      and loss of profits), damage or injury, other than (i) liability for death      or personal injury resulting from the implementation of or reliance on any      actual or alleged advice or assistance of such person or (ii) liability      resulting from the Licensor's or its representatives' negligence or wilful      misconduct. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3.4.4 | For      the avoidance of doubt, the Licensor is not required to allow any      Permitted Sub-licensee access to its facilities and/or its trade      secrets. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4 | LICENSEE'S      OBLIGATIONS |
|---|-----------------------------|

|   | The      Licensee shall at all times indemnify, and keep indemnified, the Licensor      against all or any costs, claims, damages, liabilities or expenses      incurred by the Licensor or for which the Licensor may become liable with      respect to any product liability claim relating to the Product      manufactured by the Licensee, its sub-licensee or the Third Party contract      manufacturer of Licensee or its sub-licensee.  The Licensee      shall maintain adequate product liability insurance and shall supply to      the Licensor the policy on request. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5 | IMPROVEMENTS |
|---|--------------|

|   | 5.1 | The      Licensee undertakes that subject to any obligations as to confidence, the      Licensee must immediately Disclose to the Licensor any Improvements      created or developed by, for or on behalf of the Licensee upon it becoming      aware that an Improvement has been or may be created or      developed. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 5.2 | In      consideration of the rights granted under Clause 2 with respect to      Disclosure of the Licensed Know-How, Licensed Patents, and/or the [***]      all Intellectual Property in Improvements shall vest in and be owned by      the Licensor.  The Licensee hereby assigns to the Licensor, with      full title guarantee (subject only to the obligation to assign to      Licensor), such rights, title and interest in and to any Intellectual      Property in any Improvements it owns or will own, together with any      related rights and powers arising or accrued, including but not limited to      the rights to sue for damages (and the right to retain any damages      obtained) for all past infringements.  To the extent that any      assignment of future rights is prevented by law, the Licensee shall hold      any such right on trust for the Licensor absolutely until such purported      transfer of rights is perfected.  The Licensee further agrees to      execute or procure the execution of such deeds or documents and do or      procure the doing of such acts and things as may be necessary or desirable      to perfect the transfer of title to the Licensor or effect the recording      or registration of the assignment of any such Intellectual Property to the      Licensor (all reasonable costs incurred by the Licensee in providing such      co-operation shall be paid for by the Licensor).  Any such      Improvement transferred to the Licensor hereunder shall be considered      Licensed Know-How and/or Licensed Patents for purposes of this TTL      Agreement. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6 | CONFIDENTIALITY |
|---|-----------------|

|   | 6.1 | The      Licensed Know-How and/or Licensed Patents may be Disclosed in electronic,      oral, written or other tangible form.  Any Information which is      orally or visually Disclosed to the Licensee shall constitute Licensed      Know-How: |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.1.1 | if      it would be apparent to a reasonable person, familiar with the Licensor’s      business and the industry in which it operates, that such Information is      of a confidential or proprietary nature the maintenance of which is      important to the Licensor; or |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.1.2 | if      the Licensor, within [***] after such Disclosure, delivers to the Licensee      a written document or documents describing such Information and      referencing the place and date of such oral, visual or written Disclosure      and the names of the persons at the receiving Party to whom such      Disclosure was made. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 6.2 | The      Licensee hereby represents to the Licensor that it shall not, without the      prior written consent of theLicensor: |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------|

|   | 6.2.1 | use      the Licensed Know-How and/or Licensed Patents for any purpose other than      the Approved Purpose; or |
|--------|-------|-----------------------------------------------------------------------------------------------------------------|

|   | 6.2.2 | Disclose      the Licensed Know-How to any Third Party for any purpose, except as      provided for in Clause 6.5; or |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------|

|   | 6.2.3 | publish      the Licensed Know-How or otherwise place the Licensed Know-How in the      public domain; or |
|--------|-------|-----------------------------------------------------------------------------------------------------------|

|   | 6.2.4 | duplicate      the Licensed Know-How or produce extracts or documents containing Licensed      Know-How except for limited copies, extracts or documents made as needed      and provided on a need-to-knowbasis. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.3 | Furthermore,      the Licensee undertakes not to engage in or to procure the decompilation,      disassembly, or otherwise reverse engineering of any or all of the      Licensed Know-How and/or Licensed Patents, except and only to the extent      that such activity is expressly permitted by applicable law      notwithstanding this limitation.  The terms of this Clause 6.3      shall continue to apply notwithstanding termination of this TTL Agreement      or any other cessation of any business relationship between the      Parties. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.4 | The      Licensee shall limit access to the Licensed Know-How to those of its      employees, consultants and Permitted Sub-licensees who need to receive it      for the Approved Purpose and then only to the extent deemed      necessary.  The Licensee shall ensure that such employees,      consultants and Permitted Sub-licensees are made aware of its obligations      to maintain the Licensed Know-How in confidence and shall not Disclose      Licensed Know-How to any Third Party except as permitted by this TTL      Agreement. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 6.5 | The      Licensee undertakes not to Disclose or permit to be Disclosed to any Third      Party other than to those of its officers, employees, agents, consultants,      licensees and financial investors that have a need to know the Licensed      Know-How of the Licensor for purposes of this Agreement, provided that such      Disclosure will be made under a confidentiality non-Disclosure agreement      comprising of terms at least as stringent as the confidentiality      provisions under this Clause 6.  Furthermore, the Licensee will      be entitled to Disclose the Process and the terms and conditions of this      Agreement to (i) potential licensees or collaboration partners regarding      the Product, and to (ii) potential acquirers of the Licensee, provided, however, that      such potential sub-licensees, collaboration partners or acquirers are in      [***], that such Disclosure is necessary to evaluate the respective      project , that such potential sub-licensee or collaboration partner is      [***], based on [***], and is organised and operating in the permitted      territories listed in Schedule D (but      may not be disclosed to Affiliates outside these permitted      territories)  and that such Disclosure will be made under a      confidentiality non-Disclosure agreement comprising of terms at least as      stringent as the confidentiality provisions under this Clause      6.  With respect to any other potential sub-licensees,      collaboration partners and acquirers Disclosure can only be made upon the      Licensor's prior written consent, such consent not to be unreasonably      withheld or delayed.  For the avoidance of doubt, Licensee shall      remain fully liable for any disclosure by Licensee’s potential      sub-licensee, collaboration partner or acquirer of their respective      confidentiality obligations. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.6 | The      foregoing restrictions on Disclosure and use shall not be applicable to      any Licensed Know-How which the Licensee can  demonstrate: |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.6.1 | was      rightfully in its possession prior to the date of    Disclosure; |
|--------|-------|---------------------------------------------------------------------------|

|   | 6.6.2 | was      in the public domain prior to the date of  Disclosure; |
|--------|-------|-----------------------------------------------------------------|

|   | 6.6.3 | has      subsequently entered into the public domain by publication or other means,      except by means of an unauthorised act or omission by the      Licensee; |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 6.6.4 | was      supplied to the Licensee without restriction on use or Disclosure by a      Third Party who was under no restriction directly or indirectly to the      Licensor or any of its Affiliates regarding the use or Disclosure of said      information; |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.6.5 | that      the Licensee is required by law to Disclose, provided that the      Licensor is given prompt written notice of any such requirement prior to      any Disclosure of Licensed Know-How so that it may contest such      requirement, if necessary; or |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.6.6 | was      independently developed by the Licensee or its Affiliates without access      to the Licensed Know-How and/or Licensed Patents, as evidenced by      documentary records. |
|--------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Licensed      Know-How contained within more general Information that may fall within      one or more of the exceptions; or |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | any      combination of features or items of Licensed Know-How where one or more of      the relevant individual features or items (but not the combination itself)      may fall within one or more of theexceptions. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.7 | The      non-disclosure and non-use provisions under this TTL Agreement shall      continue in force unless and until the Licensed Know-How enters the public      domain, other than through a breach of this TTL Agreement by the      Licensee. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 6.8 | In      consideration of the Licensee receiving the Licensed Know-How and/or      Licensed Patents, the Licensee acknowledges that a breach of the      provisions of this TTL Agreement by the Licensee, or any of its employees      could result in serious damage being sustained by the Licensor and as a      result the Licensee hereby agrees: |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 6.8.1 | to      indemnify the Licensor fully for any losses, damages or expenses that may      be occasioned by any such breach;and |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------|

|   | 6.8.2 | that      since money damages alone may be a wholly inadequate measure of the loss,      the Licensor shall be entitled to specific enforcement of the terms hereof      (by injunction or otherwise) on such terms as any court with jurisdiction      may deem just and proper. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7 | PAYMENTS |
|---|----------|

|   | 7.1 | In      the event the Process is based on the Lonza Process, as defined in the      Development Agreement, the Licensee shall pay within [***] after the first      regulatory approval of the Product in the United States, in the European      Union or in Japan a non-refundable and irrevocable disclosure fee in the      amount of |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | £[***]      if the [***] of such Lonza Process isused, |
|--------|-----|-------------------------------------------------------------|

|   | (b) | £[***]      if the [***] of such Lonza Process isused, |
|--------|-----|-------------------------------------------------------------|

|   | (d) | no      additional payment if the [***] of such Lonza Process are being      used, |
|--------|-----|------------------------------------------------------------------------------------|

|   | provided, however, that      if [***], the Licensee shall only be required to pay a pro-rata amount      corresponding [***] , and further provided that each of      the payments under this Clause 7.1 shall only be made once and the total      payments shall in no event exceed[***]. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.2 | In      consideration of the rights granted under Clause 2 regarding the [***],      and upon termination of the Development Agreement (i.e., in the event the      Licensor does no longer develop and manufacture the Product on behalf of      the Licensee) the Licensee shall pay to the  Licensor: |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | within      [***] of the date of this TTL Agreement the sum of [***];    and |
|--|-----|------------------------------------------------------------------------------|

----

|  | (b) | a      royalty of [***] on a country-by-country basis of the Net Selling Price of      each Product sold in the Territory by the Licensee (or its sublicensee),      such royalty being payable for as long as the manufacture, use or sale of      the Product (or any other infringing act) is covered under a Valid Claim      within the [***] (with the exception only of Improvements assigned to      Licensor under Clause 5 above);or |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.3 | To      the extent the Licensee requires a license to any Licensed Patents and/or      Licensed Know-How which is generated by the Licensor during the term of      this TTL Agreement, the Parties shall agree in good faith on any      reasonable consideration for such license, if  any. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 7.4 | The      Licensee shall keep true and accurate records and books of account      containing all data necessary for the calculation of royalties payable to      the Licensee under Clause 7.2 above.  Such records and books of      account shall, upon reasonable notice having been given by the Licensor      (which in no event shall be less than [***] prior notice), be open at all      reasonable times during regular business hours for inspection by      independent, certified and internationally recognized auditors selected by      the Licensor and reasonably acceptable to the Licensee.  Such      independent auditors shall agree to maintain the confidentiality of the      information and materials disclosed during the audit.  Any such      audit shall be conducted during regular business hours, in a manner that      does not interfere unreasonably with the operations of the Licensee’s      business and, save for cause, not more often than once every calendar      year.  Each audit shall begin upon reasonable prior written      notice to the Licensor and shall be completed as soon as reasonably      practicable.  The Licensor shall pay the costs of the      independent auditors conducting such audit, unless the results of the      audit reveal an underpayment of [***] or more by the Licensee, in which      case, the Licensee shall pay the reasonable costs of the independent      auditors.  If an audit concludes that an overpayment or      underpayment has occurred during the audited period, such payment shall be      remitted by the Party responsible for such payment to the other Party      within [***] after the date such auditor’s written report identifying the      overpayment or underpayment is delivered to the Party responsible for such      payment. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7.5 | The      Licensee shall prepare a statement in respect of each calendar quarter      which shall show for the immediately preceding quarter details of the      sales of Product and the royalty due and payable to the Licensor      thereon.  Such statement shall be submitted to the Licensor      within [***] after the end of the calendar quarter to which it relates,      together with a remittance for the royalties due to the      Licensor. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 7.6 | All      sums due under this TTLAgreement: |
|--------|-----|--------------------------------------------|

|  | 7.6.1 | shall      be made in pounds sterling to the Licensor.  Payments due to the      Licensor in currencies other than pounds sterling shall first be      calculated in the relevant local currency before being calculated at the      rate of exchange in effect at the close of business on the day payment is      due or made, whichever is earlier, provided always that      where payment is made after the date provided therefore herein conversion      shall be at the rate in effect at the date of payment if this is more      favourable to the Licensor.  The rate of exchange shall be the      mean value of the Pound Spot Rate in London first published in the      Financial Times on the day following the day for determining such      rates; |
|--|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 7.6.2 | are      exclusive of any Value Added Tax or of any other applicable taxes, levies,      imposts, duties and fees of whatever nature imposed by or under the      authority of any government or public authority, and shall be paid by the      Licensee (other than taxes on the Licensor’s income).  The      Parties agree to co-operate in all respects reasonably necessary to take      advantage of such double taxation treaties as may be      available. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 7.7 | In      the event of any delay in effecting payment due under this TTL Agreement      by the due date, the Licensee shall pay to the Licensor interest      calculated on a daily basis on the overdue payment, from the date after      such payment was due to the date of actual payment, at a rate of      [***]. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8 | PROTECTION      OF THE LICENSED KNOW-HOW |
|---|------------------------------------------|

|  | 8.1 | In      the event that any unlicensed activities are carried on by any Third Party      which could constitute unauthorised Disclosure or the misuse of any of the      Licensed Know-How, the Party becoming aware of such a matter shall      immediately notify the other of it, and the Licensee shall join the      Licensor in taking all steps (if any) as, in the total discretion of the      Licensor, shall be desirable for the protection of the Licensor's rights      under the Licensed Know-How.  The expenses incurred in taking      such steps, and any profits or damages which may be obtained, shall be (in      the absence of any agreement to the contrary) for the account of the      Licensor. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 8.2 | Subject      only to Clause 9 below, nothing in this TTL Agreement shall constitute any      representation that the Products or the use of the Licensed Know-How does      not fall within the scope of any Third Party Intellectual      Property. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9 | WARRANTIES      AND INDEMNITIES |
|---|---------------------------------|

|  | 9.1 | Each      of the Parties warrants that it has full power and authority to carry out      the actions contemplated under this TTL Agreement, and that its entry into      and performance under the terms of this TTL Agreement will not infringe      the rights of any Third Party or cause it to be in breach of any      obligations to a Third Party. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 9.2 | The      Licensor warrants to the Licenseethat: |
|--|-----|-------------------------------------------------|

|  | 9.2.1 | all      Information, data and materials provided by it to the Licensee hereunder      will be, to the best of its knowledge, accurate and complete in all      material respects, and it is entitled to provide the same to the Licensee      without recourse to any Third Party;and |
|--|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 9.2.2 | to      the best of its knowledge and belief, the Information, the Licensed      Know-How, the Licensed Patents and/or the [***] do not infringe, the      rights of any Third Party, and no Third Party has threatened or, so far as      it is aware, is currently threatening proceedings in respect of such      infringement, and none of its Information, the Licensed Know-How, the      Licensed Patents and/or the [***] is the subject of any actual or, so far      as it is aware, threatened challenge or opposition or revocation      proceedings; and |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 9.2.3 | to      the best of its knowledge and belief, the [***] if used per the      instructions provided by the Licensor is suitable for the Approved      Purpose.  If during the term of this TTL Agreement Licensor      learns that the [***] is not suitable for the Approved Purpose or causes      adverse effects, the Licensor shall promptly inform the Licensee hereof;      and |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 9.2.4 | to      the best of its knowledge and belief, the suppliers of [***] and [***]      will be able and willing to supply such [***] to the Licensee or its      sublicensee or Third Party contract manufacturer of Licensee or      sublicensee for the manufacture of the Product for clinical and commercial      supply at terms and conditions of supply customary in the      industry. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.3 | Each      Party (“Indemnifying      Party”) shall defend, indemnify and hold harmless the other Party      (“Indemnified      Party”) and its directors, officers, employees and agents and the      successors and assigns of any of the foregoing at all times from and      against any Third Party claims actions, liabilities, costs and expenses      (including court costs and legal fees on a full indemnity basis) that the      Indemnified Party may suffer arising directly out of the Indemnifying      Party’s breach of this TTL Agreement, including breach of representations      and warranties, violation of applicable law, or the Indemnifying Party's      negligent or wilful act oromission. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.4 | With      respect to liability claims or proceedings, the following shall apply; (a)      except to the extent provided in (b) below, the Licensee shall indemnify      and hold harmless the Licensor and its directors, officers, employees and      agents and the successors and assigns of any of the foregoing at all times      from any against any Third Party claims, actions, liabilities, costs and      expenses (including court costs and legal fees on a full indemnity basis)      that the Indemnified Party may suffer as a direct result of any tortious      claims or proceedings of death or bodily injury relating to the Product      and this TTL Agreement, and (b) the Licensor shall indemnify and hold      harmless the Licensee and its directors, officers, employees and agents      and the successors and assigns of any of the foregoing at all times from      any against any Third Party claims, actions, liabilities, costs and      expenses (including court costs and legal fees on a full indemnity basis)      that the Indemnified Party may suffer as a direct result of any tortious      claims or proceedings of death or bodily injury relating to the Product to      the extent such claims or proceedings result from defects in the      Information, the Licensed Know-How or the Licensed Patents, or from      Licensor's breach of this TTLAgreement. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 9.5 | If      an Indemnified Party intends to claim indemnification under this Clause 9,      it shall promptly notify the Indemnifying Party in writing of such alleged      liability.  The Indemnifying Party shall have the right to      control the defence thereof with counsel of its choice as long as such      counsel is reasonably acceptable to Indemnified Party; provided, however,      that the      Indemnified Party shall have the right to retain its own counsel at its      own expense, for any reason, including if representation of the      Indemnified Party by the counsel retained by the Indemnifying would be      inappropriate due to actual or potential differing interests between such      Indemnified Party and any the Indemnifying Party.  The      Indemnified Party, its employees and agents, shall reasonably cooperate      with the Indemnifying Party and its legal representatives in the      investigation of any liability covered by this Clause 9.  The      obligations of this Clause 9 shall not apply to amounts paid in settlement      of any claim, demand, action or other proceeding if such settlement is      effected without the consent of the Indemnifying Party, which consent      shall not be withheld or delayed unreasonably.  The failure to      deliver written notice to the Indemnifying Party within a reasonable time      after the commencement of any such action, if prejudicial to its ability      to defend such action, shall relieve the Indemnifying Party of any      obligation to the Indemnified Party under this Clause 9.  It is      understood that only the Licensor and the Licensee may claim indemnity      under this Clause 9 (on its own behalf or on behalf of its indemnitees),      and other indemnitees may not directly claim indemnity      hereunder. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9.6 | Any      condition or warranty other than those set forth in Clause 9.2 and/or      relating to title which might otherwise be implied or incorporated within      this TTL Agreement by reason of statute or common law or otherwise is      hereby expressly excluded. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 9.7 | IN      NO EVENT (OTHER THAN WILFUL MISCONDUCT) SHALL EITHER PARTY BE LIABLE TO      THE OTHER PARTY FOR LOSS OF PROFITS, SPECIAL, INDIRECT, INCIDENTAL,      PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS TTL      AGREEMENT. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10 | DURATION      AND TERMINATION |
|----|-------------------------------|

|   | 10.1 | This      TTL Agreement shall come into force on the Effective Date of this TTL      Agreement and shall, unless terminated in accordance with Clause 10.2 or      10.3 below, remain in force until the Licensee has no further need to use      the Information, the Licensed Know-How, the Licensed Patents and/or the      [***]. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.2 | The      Licensee shall be entitled to terminate this TTL Agreement at any time by      giving [***] prior written notice. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------|

|   | 10.3 | The      Licensor shall have the right to terminate this TTL Agreement immediately      by notice in writing to theLicensee |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------|

|  | (i) | in      the event that the Licensee fails to perform or observe any of the      obligations on its part to be performed or observed under this TTL      Agreement, provided, that, in a case where the breach is remediable, such      notice from the Licensor shall also require the Licensee to remedy such      breach and if the Licensee so remedies within [***], in the event of a      breach of [***], and within [***], in the event of any other breach, of      such notice being served, such notice to terminate this TTL Agreement      shall be deemed to be void and of no effect;or |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | (ii) | in      the event an interim order is applied for or made, or a voluntary      arrangement approved, or a petition for a bankruptcy order is presented or      a bankruptcy order is made against the Licensee, or a receiver or trustee      in bankruptcy is appointed of the Licensee's estate or a voluntary      arrangement is proposed or approved or an administration order is made, or      a receiver or administrative receiver is appointed of any of the      Licensee's assets or undertaking, or a winding-up resolution or petition      is passed or presented (otherwise than for the purposes of reconstruction      or amalgamation), or any circumstances arise which entitle the court, a      creditor, the company or its directors to appoint a receiver,      administrative receiver or administrator or to present a winding-up      petition or make a winding-up order or other similar or equivalent action      is taken against or by the Licensee by reason of its insolvency or in      consequence of debt, and      provided that following such proceedings the Licensee is Controlled      by companies, partnerships and/or other entities which are registered and      operating, with respect to the manufacturing of the Product, outside the      permitted territories listed in Schedule      D. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.4 | Upon      termination of this Agreement in accordance with Clause 10.3 (i), the      Licensee shall offer to each sublicensee and/or sub-sublicensee a direct      license agreement on substantially the same the terms and conditions as      this TTL Agreement, provided, however, that      the Licensor is not required to grant such direct licence if the      sublicensee is in breach of its sublicense agreement at the time such      direct licence is to be granted. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.5 | In      the event of expiry or termination of this TTL Agreement for any reason,      and subject to any express provisions set out elsewhere in this TTL      Agreement: |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.5.1 | all      rights and licences shallcease; |
|--|--------|------------------------------------------|

|  | 10.5.2 | the      Licensee shall cease all exploitation of the Licensed Know-How and/or      Licensed Patents and any other know-how provided by the Licensor to the      Licensee, except insofar as the Licensed Know-How, or such other know-how,      ceases or has ceased to be confidential, unless this is or was as a      consequence of the default of theLicensee; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.5.3 | the      Licensee shall return promptly to the Licensor all technical material in      its possession relating to the Information, the Licensed Know-How and/or      the Licensed Patents and all copies of such material to the extent that      such material remainsconfidential; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 10.5.4 | the      Licensee shall have the right to dispose of all stocks of the Product in      its possession and all Product in the course of manufacture at the date of      termination; and |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10.5.5 | irretrievably      delete any Licensed Know-How, stored on any magnetic or optical disk or      memory and all matter derived from such sources which is in its possession      or under its control. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.6 | The      expiry or termination of this Agreement for any reason shall be without      prejudice to the provisions of this Clause 10 and to any rights of either      Party which may have accrued by, at or up to the date of such      termination. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11 | ASSIGNMENT |
|----|------------|

| 12 | SEVERANCE |
|----|-----------|

----

| 13 | NO      WAIVER |
|----|----------------|

| 14 | VARIATION |
|----|-----------|

| 15 | FURTHER      ASSURANCE |
|----|------------------------|

| 16 | ENTIRE      AGREEMENT; SURVIVAL |
|----|---------------------------------|

|   | 16.1 | This      TTL Agreement and the documents referred to in it, constitute the entire      agreement and understanding of the Parties and upon the Effective Date of      this TTL Agreement supersede any previous agreement between the Parties      relating to the subject matter of this TTL Agreement.  For the      avoidance of doubt, the [***] dated [***] shall not apply to the      manufacture of the Product. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 16.2 | Each      of the Parties acknowledges and agrees that, in entering into this TTL      Agreement and the documents referred to in it, it does not rely on, and      shall have no remedy in respect of, any statement, representation,      warranty or understanding (whether negligently or innocently made) of any      person (whether party to this TTL Agreement or not) other than as      expressly set out in this TTL Agreement as a warranty or      representation.  The only remedy available to it for breach of      such warranties or representations shall be for breach of contract under      the terms of this TTL Agreement.  Nothing in this clause shall      operate to limit or exclude any liability for  fraud. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 16.3 | The      obligations of the Parties under Clauses 4 (The Licensee's Obligations), 5      (Improvements), 6 (Confidentiality), 9 (Warranties and Indemnities) and      10.4 (consequences of termination) shall survive the termination of this      Agreement for any reason. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 17 | NOTICE |
|----|--------|

|   | 17.1 | Any      notice or other communication to be given under this TTL Agreement shall      be delivered personally or sent by facsimile transmission, or if facsimile      transmission is not available, by first class pre-paid post addressed as      follows: |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)    | If      to Lonza to:                         | Lonza      Sales AG                                   |
|--------|----------------------------------------------|-------------------------------------------------------|
|   |                                         | Muenchensteinerstrasse      38                        |
|   |                                         | CH-4402      Basel                                    |
|   |                                         | Switzerland                                           |
|   |                                         | Facsimile:      +41 61      316 8329                  |
|   |                                         | Attention:  The      Head of Legal Services |
|   |                                         |                                                  |
|   | with      a copy to:                         | Lonza      Biologics plc                              |
|   |                                         | 228      Bath Road                                    |
|   |                                         | Slough                                                |
|   |                                         | Berkshire      SL1 4DX                                |
|   |                                         | England                                               |
|   | Facsimile:                                   | +44      1753 777001                                  |
|   | For      the attention of:                   | The      Head of Legal Services                       |
|   |                                         |                                                  |
| (b)    | If      to Micromet to:                      | Micromet      AG                                      |
|   |                                         | Staffelseestrasse      2                              |
|   |                                         | D-81477      Munich                                   |
|   |                                         | Germany                                               |
|   | Facsimile:                                   | +49-89-895      277 205                               |
|   | For      the attention of:    | Head      of BusinessDevelopment                      |

----

|   | with      a copy to:     | Micromet,      Inc.           |
|--------|----------------------------------------------|-------------------------------|
|   |                                         | 6707      Democracy Boulevard |
|   |                                         | Suite      505                |
|   |                                         | Bethesda,      MD 20817       |
|   |                                         | United      States of America |
|   | Attention:                                   | General      Counsel          |
|   | Facsimile:                                   | +1      240752-1425           |

|   | or      to such other destination as either Party hereto may hereafter notify to      the other in accordance with the provisions of this Clause    17. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 17.2 | All      such notices or other communications shall be deemed to have been served      as follows: |
|--------|------|----------------------------------------------------------------------------------------------------|

|   | (a)  | if      delivered personally, at the time of such  delivery; |
|--------|-----------|--------------------------------------------------------------|

|   | (b) | if      sent by facsimile, upon receipt of the transmission confirmation slip      showing completion of thetransmission; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------|

|   | (c) | if      sent by first class pre-paid post, ten (10) business days (Saturdays,      Sundays and Bank or other public holidays excluded) after being placed in      the post. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18 | GOVERNING      LAW, DISPUTE RESOLUTION |
|----|----------------------------------------|

|   | 18.1 | The      construction, validity and performance of the TTL Agreement shall be      governed by the laws ofSwitzerland. |
|--------|------|------------------------------------------------------------------------------------------------------------------------|

|   | 18.2 | No      failure or delay on the part of either Licensor or Licensee to exercise or      enforce any rights conferred on it by this TTL Agreement shall be      construed or operate as a waiver thereof nor shall any single or partial      exercise of any right, power or privilege or further exercise thereof      operate so as to bar the exercise or enforcement thereof at any time or      times thereafter. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.3 | Any      disputes relating to issues arising from this TTL Agreement shall, in the      absence of resolution within [***] of the dispute arising, be referred to      the CEOs of Licensee and COO of Licensor, who shall discuss the matter and      attempt to resolve it by mutual consent.  The CEOs of Licensee      and COO of Licensor shall meet once face-to-face within [***] to discuss      and resolve the dispute.  If the dispute cannot be resolved      within [***], either Party may, by written notice to the other Party,      invoke the mediation procedure set out in Clause 18.4    below. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 18.4 | If      a dispute arises between the Parties that the Parties cannot resolve      pursuant to Clause 18.3 above, the Parties agree to try to solve such      dispute amicably by mediation.  The Parties shall conduct a      mediation procedure according to the ICC ADR Rules of the International      Chamber of Commerce (ICC) in effect on the date of the commencement of the      mediation proceedings.  The location of the mediation      proceedings will be Basel.  The number of mediators will be one      (1).  The language of the mediation proceeding will be      English.  If the dispute has not been settled pursuant to the      said rules within [***] following the filing of a request for mediation or      within such other period as the Parties may agree in writing, either Party      may submit the dispute to final and binding  arbitration. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.5 | Any      dispute relating to the validity, performance, construction or      interpretation of this TTL Agreement, which cannot be resolved amicably      between the Parties, shall be submitted to arbitration in accordance with      the ICC Arbitration Rules of the International Chamber of      Commerce.  Save in the face of manifest error, the decision of      the arbitrators shall be final and binding upon the Parties and      enforceable in any court of competent jurisdiction.  The      location of arbitration will be Basel.  The arbitration will be      heard and determined by one (1) arbitrator, who will be jointly selected      by Licensor and Licensee.  If, within [***] following the date      upon which a claim is received by the respondent, the Parties cannot agree      on a single arbitrator, the arbitration will be heard and determined by      three (3) arbitrators, with one arbitrator being appointed by each Party      and the third arbitrator being selected by the two Party-appointed      arbitrators.  If either Party fails to select an arbitrator, or      if the Party-appointed arbitrators cannot agree on a third arbitrator      within [***] of the respondent receiving the claim, such arbitrator will      be appointed by the International Court of Arbitration according to the      ICC Rules.  The arbitration award that is consistent with the      provisions of this TTL Agreement that is so given will be binding upon the      Parties, accompanied by a reasoned opinion in writing (in English), and      the judgment on the award may be entered in any court having competent      jurisdiction thereof. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 18.6 | Each      Party will bear its own costs and expenses (including its attorney’s fees)      associated with any arbitration initiated under this Clause, and each      Party will bear an equal share of the arbitrators’ and administrative fees      associated with any arbitration initiated under this      Clause.  The language of the arbitration proceeding will be      English.  Notwithstanding the foregoing, Parties agree that the      non-prevailing Party shall reimburse the costs of the prevailing      Party. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 18.7 | Notwithstanding      the provisions of Clause 18.5, each Party shall have the right to seek,      without proof of special damage, a preliminary, permanent injunctive or      other equitable relief in any court of competent jurisdiction as such      Party deems necessary to preserve its rights and to protect its      interests. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Signed      byfor      and on behalf of LONZA      SALES AG  | .......................................        |
|-------------------------------------------------------------------|-----------------------------------------------------|
| Signed      byfor      and on behalf of LONZA      SALES AG  | .......................................        |
| Signed      byfor      and on behalf of MICROMET      AG          | .......................................   |
| Signed      byfor      and on behalf of MICROMET      AG          | .......................................        |

----

----

----

----

|   | · | USA |
|--------|--------|-----|

|   | · | EU,      EFTA and Switzerland |
|--------|--------|-------------------------------|

|   | · | Japan |
|--------|--------|-------|

|   | · | Australia |
|--------|--------|-----------|

|   | · | New      Zealand |
|--------|--------|------------------|

|   | · | Canada |
|--------|--------|--------|

| Contract      Manufacturing Organization(and      their Affiliates in the permitted territories listedabove) | Company      Details |
|--------------------------------------------------------------------------------------------------------------|----------------------|
| [***]                                                                                                        |  [***]     |
| [***]                                                                                                        |  [***]     |
| [***]                                                                                                        |  [***]     |
| [***]                                                                                                        |  [***]     |
| [***]                                                                                                        | [***]                |
| [***]                                                                                                        | [***]                |
| [***]                                                                                                        | [***]                |
| [***]                                                                                                        | [***]                |

----

| Lonza      Group Ltd               | Lonza      Group Ltd     | Lonza      Group Ltd     |
|------------------------------------|--------------------------|--------------------------|
| Head      Corporate Communications | Media      Relations     | Investor      Relations  |
| Michael      Frizberg              | Dominik      Werner      | Dirk      Oehlers        |
| Tel      +41 61 316 8624           | Tel      +41 61 316 8798 | Tel      +41 61 316 8540 |
| Fax      +41 61 316 9624           | Fax      +41 61 316 9798 | Fax      +41 61 316 9540 |
| michael.frizberg@lonza.com         | dominik.werner@lonza.com | dirk.oehlers@lonza.com   |

----

----

| US      Media:                   | European      Media:     |
|----------------------------------|--------------------------|
| Andrea      tenBroek/Chris Stamm | Ludger      Wess         |
| (781)-684-0770                   | +49      (40) 8816 5964  |
| micromet@schwartz-pr.com         | ludger@akampion.com      |
|                             |                     |
| US      Investors:               | European      Investors: |
| Susan      Noonan                | Ines-Regina      Buth    |
| (212)      966-3650              | +49      (30) 2363 2768  |
| susan@sanoonan.com               | ines@akampion.com        |

----